Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0004053 arginase activity	IBA GO_REF:0000033	ACCEPT	Summary: Phylogenetic (PAN-GO) inference of arginase activity, the defining and core molecular function of ARG1. Reason: This is the correct, specific molecular function. Arginase activity (EC 3.5.3.1, L-arginine + H2O = L-ornithine + urea) is directly demonstrated for human ARG1 by crystallographic and enzymatic studies, so the IBA inference is strongly supported. Supporting Evidence: PMID:17562323 Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea.
GO:0005737 cytoplasm	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: Phylogenetic inference that ARG1 acts in the cytoplasm; consistent with its established cytosolic localization. Reason: Correct but non-specific. ARG1 is a cytosolic enzyme; the more precise term GO:0005829 (cytosol), also annotated, better captures the localization. Retained as it is not wrong, but subordinate to the cytosol annotation. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0006525 arginine metabolic process	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: Phylogenetic inference that ARG1 participates in arginine metabolism; correct but general. Reason: Accurate at a general level. ARG1 catabolizes L-arginine, so involvement in arginine metabolism is correct; the more specific L-arginine catabolic process (GO:0006527) and urea cycle (GO:0000050) annotations capture the precise role. Supporting Evidence: PMID:17562323 Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea.
GO:0042130 negative regulation of T cell proliferation	IBA GO_REF:0000033	KEEP AS NON CORE	Summary: Phylogenetic inference of an immunoregulatory role in suppressing T-cell proliferation, corroborated by direct experimental evidence in human granulocyte arginase. Reason: Well-supported secondary (myeloid/immune) function. Extracellular arginase released from human granulocytes depletes arginine and suppresses T-cell proliferation. This is a genuine role but distinct from the core hepatic urea-cycle function. Supporting Evidence: PMID:16709924 Human granulocyte arginase induces a profound suppression of T-cell proliferation and cytokine synthesis.
GO:0000050 urea cycle	IBA GO_REF:0000033	ACCEPT	Summary: Phylogenetic inference that ARG1 participates in the urea cycle; this is a core biological process for the enzyme. Reason: ARG1 catalyzes the terminal step of the urea cycle, regenerating ornithine and releasing urea. This is a core biological process and the IBA inference is strongly supported by direct evidence. Supporting Evidence: PMID:3540966 Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle in the liver of ureotelic animals.
GO:0030145 manganese ion binding	IBA GO_REF:0000033	ACCEPT	Summary: Phylogenetic inference of manganese ion binding; ARG1 requires a binuclear Mn(2+) cluster for catalysis. Reason: Directly supported by high-resolution crystal structures showing two manganese ions per subunit forming the catalytic binuclear cluster. Core molecular function cofactor requirement. Supporting Evidence: PMID:16141327 The ultrahigh-resolution structure of the human arginase I-ABH complex yields an unprecedented view of the binuclear manganese cluster
GO:0005829 cytosol	IBA GO_REF:0000033	ACCEPT	Summary: Phylogenetic inference that ARG1 acts in the cytosol; this is the established subcellular location of type I arginase. Reason: Arginase I is a cytosolic enzyme (in contrast to mitochondrial ARG2). This is the core localization where ureagenic arginine hydrolysis occurs. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0004053 arginase activity	IEA GO_REF:0000120	ACCEPT	Summary: Automated (multiple-method) inference of arginase activity, mapped from RHEA:20569/EC:3.5.3.1 and orthology. Reason: Correct and specific molecular function, consistent with the RHEA reaction L-arginine + H2O = L-ornithine + urea and the experimental annotations. Duplicate of the IBA/EXP arginase-activity annotations, which is acceptable. Supporting Evidence: PMID:16141327 we demonstrate the inhibition of arginase activity by ABH in human and murine myeloid cells
GO:0005737 cytoplasm	IEA GO_REF:0000044	KEEP AS NON CORE	Summary: Automated mapping from the UniProt Cytoplasm subcellular-location keyword. Reason: Correct but general; cytosol (GO:0005829) is the more precise term for this cytosolic enzyme. Retained as a valid broader localization. Supporting Evidence: PMID:16141327 exploration of inhibition in the immune response
GO:0006525 arginine metabolic process	IEA GO_REF:0000002	KEEP AS NON CORE	Summary: InterPro2GO mapping (arginase domain) to arginine metabolic process. Reason: Correct but general. The specific catabolic role (L-arginine catabolic process, GO:0006527) and urea cycle (GO:0000050) better capture ARG1's function; this broad parent is acceptable as an IEA. Supporting Evidence: PMID:17562323 Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea.
GO:0016813 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines	IEA GO_REF:0000002	MODIFY	Summary: InterPro2GO mapping (ureohydrolase Mn-binding site) to a broad hydrolase-on-C-N-linear-amidines term. Reason: This is the parent term of the specific and experimentally established arginase activity (GO:0004053). Arginase hydrolyzes the C-N bond of the linear amidine L-arginine, so the term is not wrong, but it is over-general given the precise activity is known. Replace with the specific molecular function. Proposed replacements: arginase activity Supporting Evidence: PMID:21728378 Arginase is a binuclear manganese metalloenzyme that hydrolyzes L-arginine to form L-ornithine and urea
GO:0042127 regulation of cell population proliferation	IEA GO_REF:0000117	MARK AS OVER ANNOTATED	Summary: ARBA machine-learning inference of a general role in regulating cell population proliferation. Reason: Overly general electronic annotation. ARG1's proliferation-related effects are specifically on immune cells via arginine depletion (captured by the more specific negative regulation of T-cell proliferation terms). This broad, direction-less parent adds no functional specificity and is likely an over-annotation. Supporting Evidence: PMID:16709924 Human granulocyte arginase induces a profound suppression of T-cell proliferation and cytokine synthesis.
GO:0046872 metal ion binding	IEA GO_REF:0000002	MODIFY	Summary: InterPro2GO mapping to a generic metal ion binding term. Reason: The specific metal bound is known to be manganese (a binuclear Mn(2+) cluster, two ions per subunit), captured by GO:0030145 (manganese ion binding), which is also annotated. The generic parent should be specialized. Proposed replacements: manganese ion binding Supporting Evidence: PMID:16141327 The ultrahigh-resolution structure of the human arginase I-ABH complex yields an unprecedented view of the binuclear manganese cluster
GO:0042832 defense response to protozoan	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl-Compara orthology transfer from mouse Arg1 (Q61176) of a role in antiprotozoal defense. Reason: This is an orthology-transferred (GO_REF:0000107, from mouse) immune role consistent with ARG1's known myeloid arginine-depletion function in antimicrobial defense, but it is a peripheral/species-informed role rather than the core hepatic function. Retained as non-core; the underlying human evidence is indirect. Supporting Evidence: PMID:15546957 arginase I is localized in azurophil granules of neutrophils and constitutes a novel antimicrobial effector pathway, likely through arginine depletion in the phagolysosome
GO:0046007 negative regulation of activated T cell proliferation	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl-Compara orthology transfer from mouse Arg1 of negative regulation of activated T-cell proliferation. Reason: Consistent with the well-documented human function whereby extracellular/granulocyte arginase depletes arginine and suppresses T-cell proliferation. A genuine secondary immunoregulatory role; retained as non-core. Supporting Evidence: PMID:16709924 Human granulocyte arginase induces a profound suppression of T-cell proliferation and cytokine synthesis.
GO:2000552 negative regulation of T-helper 2 cell cytokine production	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: Ensembl-Compara orthology transfer from mouse Arg1 of a role in limiting Th2 cytokine production. Reason: Orthology-transferred (from mouse) immunoregulatory role. ARG1's arginine depletion suppresses T-cell cytokine synthesis; this specific Th2 term reflects the mouse ILC2/type-2 inflammation context. Retained as a plausible non-core immune role; the direct human evidence is limited. Supporting Evidence: PMID:16709924 Human granulocyte arginase induces a profound suppression of T-cell proliferation and cytokine synthesis.
GO:0000050 urea cycle	IEA GO_REF:0000041	ACCEPT	Summary: UniPathway mapping (UPA00158) to the urea cycle. Reason: Correct core biological process. ARG1 performs the terminal step of the urea cycle. Duplicate of the IBA urea-cycle annotation, which is acceptable. Supporting Evidence: PMID:3540966 Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle in the liver of ureotelic animals.
GO:0070947 neutrophil-mediated killing of fungus	IMP PMID:15546957 Arginase I is constitutively expressed in human granulocytes...	KEEP AS NON CORE	Summary: Experimental (IMP) annotation from the study showing arginase I in azurophil granules participates in fungicidal activity of human neutrophils. Reason: Supported by the cited experimental study demonstrating a granulocyte antimicrobial effector role via arginine depletion. This is a genuine, well-evidenced secondary function in myeloid cells, distinct from the core hepatic urea-cycle role. Note UniProt now uses the closely related term GO:0070965 (positive regulation of neutrophil mediated killing of fungus) for the same evidence. Supporting Evidence: PMID:15546957 arginase I is localized in azurophil granules of neutrophils and constitutes a novel antimicrobial effector pathway, likely through arginine depletion in the phagolysosome
GO:0006527 L-arginine catabolic process	IMP PMID:22959135 Analysis of novel ARG1 mutations causing hyperargininemia an...	ACCEPT	Summary: Experimental (IMP) annotation from analysis of ARG1 mutations causing hyperargininemia, correlating loss of arginase activity with impaired L-arginine catabolism. Reason: Core biological process. ARG1 catalyzes the breakdown of L-arginine; loss-of-function mutations cause hyperargininemia (accumulation of arginine), directly demonstrating its role in L-arginine catabolism. The curator assessed erythrocyte enzyme activity across a patient mutation series. Supporting Evidence: PMID:22959135 It is caused by the deficient activity of the enzyme arginase I, encoded by the gene ARG1.
GO:0005829 cytosol	TAS Reactome:R-HSA-9956512	ACCEPT	Summary: Reactome traceable-author annotation (ARG1 variant reaction) placing ARG1 in the cytosol. Reason: Correct core localization for the cytosolic type I arginase. Consistent with the IBA cytosol annotation and biochemical evidence. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0004053 arginase activity	EXP PMID:16141327 Crystal structure of human arginase I at 1.29-A resolution a...	ACCEPT	Summary: Direct experimental evidence of arginase activity from the 1.29-A crystal structure and inhibition study of human arginase I. Reason: Core molecular function established by direct enzymatic assay and structural characterization of catalysis, including inhibition of arginase activity in human myeloid cells. Supporting Evidence: PMID:16141327 we demonstrate the inhibition of arginase activity by ABH in human and murine myeloid cells
GO:0004053 arginase activity	EXP PMID:17562323 Expression, purification, assay, and crystal structure of pe...	ACCEPT	Summary: Direct experimental evidence that (perdeuterated) human arginase I catalyzes hydrolysis of L-arginine to L-ornithine and urea with wild-type activity. Reason: Core molecular function, directly assayed. The enzyme is explicitly characterized as a manganese metalloenzyme catalyzing L-arginine hydrolysis. Supporting Evidence: PMID:17562323 Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea.
GO:0004053 arginase activity	EXP PMID:21728378 Binding of alpha,alpha-disubstituted amino acids to arginase...	ACCEPT	Summary: Direct experimental evidence (kinetic assay plus crystal structures) of human arginase I catalytic activity. Reason: Core molecular function, directly measured. The enzyme is characterized as a binuclear manganese metalloenzyme hydrolyzing L-arginine to L-ornithine and urea. Supporting Evidence: PMID:21728378 Arginase is a binuclear manganese metalloenzyme that hydrolyzes L-arginine to form L-ornithine and urea
GO:0005737 cytoplasm	EXP PMID:16141327 Crystal structure of human arginase I at 1.29-A resolution a...	KEEP AS NON CORE	Summary: Experimental subcellular localization of ARG1 to the cytoplasm. Reason: Correct but general. The more precise cytosol term (GO:0005829) better captures the localization of this cytosolic enzyme. Retained as a valid broader annotation. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0005515 protein binding	IPI PMID:28813417 CMTM6 maintains the expression of PD-L1 and regulates anti-t...	MARK AS OVER ANNOTATED	Summary: IPI annotation recording an ARG1-CMTM6 interaction detected by mass spectrometry in a study focused on CMTM6-mediated regulation of PD-L1. Reason: Bare "protein binding" is uninformative and does not describe a molecular function. The supporting paper is a CRISPR/proteomics study of CMTM6 as a regulator of PD-L1; ARG1 appears only as one mass-spectrometry co-precipitant of CMTM6, with no evidence that this interaction is functionally relevant to ARG1. Per curation guidelines, avoid uninformative protein binding terms; this should not be treated as a core function. Supporting Evidence: PMID:28813417 CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression.
GO:0005576 extracellular region	IDA PMID:16709924 Suppression of T-cell functions by human granulocyte arginas...	KEEP AS NON CORE	Summary: Direct experimental evidence that arginase I is liberated from human granulocytes and accumulates extracellularly during inflammation. Reason: Genuine, experimentally demonstrated secondary localization. Neutrophil arginase is released into the extracellular space, where it depletes arginine. This is real but peripheral to the core intracellular (cytosolic) hepatic function. Supporting Evidence: PMID:16709924 arginase I is liberated from human granulocytes, and very high activities accumulate extracellularly during purulent inflammatory reactions
GO:0042130 negative regulation of T cell proliferation	IDA PMID:16709924 Suppression of T-cell functions by human granulocyte arginas...	KEEP AS NON CORE	Summary: Direct experimental evidence that human granulocyte arginase suppresses T-cell proliferation via arginine depletion. Reason: Well-supported secondary immunoregulatory function. Extracellular arginase depletes arginine, downregulating CD3-zeta and suppressing T-cell proliferation. Genuine but distinct from the core urea-cycle role. Supporting Evidence: PMID:16709924 This T-cell phenotype is due to arginase-mediated depletion of arginine in the T-cell environment, which leads to CD3zeta chain down-regulation but does not alter T-cell viability
GO:0060336 negative regulation of type II interferon-mediated signaling pathway	IMP PMID:16709924 Suppression of T-cell functions by human granulocyte arginas...	KEEP AS NON CORE	Summary: IMP annotation of a downstream effect on IFN-gamma signaling, linked to arginase-mediated suppression of T-cell cytokine synthesis. Reason: A downstream immunoregulatory consequence of arginine depletion (suppressed T-cell cytokine synthesis, including IFN-gamma responses) rather than a direct biochemical function of ARG1. Retained as non-core; the curator (UniProt) made this annotation from the full text. Supporting Evidence: PMID:16709924 Human granulocyte arginase induces a profound suppression of T-cell proliferation and cytokine synthesis.
GO:0005576 extracellular region	TAS Reactome:R-HSA-6798749	KEEP AS NON CORE	Summary: Reactome annotation (exocytosis of specific granule lumen proteins) placing ARG1 in the extracellular region upon neutrophil degranulation. Reason: Consistent with the experimentally demonstrated release of neutrophil arginase into the extracellular space during degranulation. A genuine secondary localization, non-core relative to the cytosolic hepatic function. Supporting Evidence: PMID:16709924 arginase I is liberated from human granulocytes, and very high activities accumulate extracellularly during purulent inflammatory reactions
GO:0005576 extracellular region	TAS Reactome:R-HSA-6798751	KEEP AS NON CORE	Summary: Reactome annotation (exocytosis of azurophil granule lumen proteins) placing ARG1 in the extracellular region upon neutrophil degranulation. Reason: Same as the other extracellular-region annotations - reflects release of granule-stored neutrophil arginase. Genuine secondary localization; non-core. Supporting Evidence: PMID:15546957 arginase I is localized in azurophil granules of neutrophils and constitutes a novel antimicrobial effector pathway, likely through arginine depletion in the phagolysosome
GO:0035578 azurophil granule lumen	TAS Reactome:R-HSA-6798751	KEEP AS NON CORE	Summary: Reactome annotation placing ARG1 in the azurophil granule lumen of neutrophils. Reason: Directly supported by experimental localization of arginase I to azurophil granules of neutrophils. A genuine myeloid-cell localization, non-core relative to the core cytosolic hepatic function. Supporting Evidence: PMID:15546957 arginase I is localized in azurophil granules of neutrophils and constitutes a novel antimicrobial effector pathway, likely through arginine depletion in the phagolysosome
GO:0035580 specific granule lumen	TAS Reactome:R-HSA-6798749	KEEP AS NON CORE	Summary: Reactome annotation placing ARG1 in the specific granule lumen of neutrophils. Reason: Reflects the granule storage of arginase I in neutrophils (the primary experimental report emphasizes azurophil granules; Reactome models both granule compartments). Genuine myeloid localization, non-core. Supporting Evidence: PMID:15546957 in human leukocytes arginase I is constitutively expressed only in granulocytes
GO:0005634 nucleus	HDA PMID:21630459 Proteomic characterization of the human sperm nucleus.	MARK AS OVER ANNOTATED	Summary: High-throughput proteomics detection of ARG1 in an isolated human sperm nucleus fraction. Reason: This annotation derives from a large-scale catalog of 403 proteins detected in isolated sperm nuclei, not from a targeted study of nuclear ARG1 function. ARG1 is a well-established cytosolic enzyme with no known nuclear function; the detection likely reflects abundant cytoplasmic protein carryover in a bulk proteomic fraction. Marked as over-annotated rather than removed, as a mass-spec detection. Supporting Evidence: PMID:21630459 403 different proteins have been identified from the isolated sperm nuclei
GO:0005829 cytosol	TAS Reactome:R-HSA-70569	ACCEPT	Summary: Reactome annotation (arginine + H2O => ornithine + urea reaction) placing ARG1 in the cytosol. Reason: Core localization. This Reactome reaction is precisely the arginase reaction, correctly localized to the cytosol where the cytosolic type I arginase acts. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0005829 cytosol	TAS Reactome:R-HSA-9959871	ACCEPT	Summary: Reactome annotation (ARG1 gene expression) associated with cytosolic localization. Reason: Correct core localization for the cytosolic type I arginase; duplicate of the other cytosol annotations, which is acceptable. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0004053 arginase activity	TAS PMID:3540966 Molecular cloning and nucleotide sequence of cDNA for human ...	ACCEPT	Summary: Traceable-author statement of arginase activity from the original cloning of human liver arginase cDNA. Reason: Core molecular function. The cloned cDNA conferred arginase activity on E. coli, and the enzyme is identified as EC 3.5.3.1 catalyzing the last urea-cycle step. Duplicate of the experimental arginase-activity annotations, which is acceptable. Supporting Evidence: PMID:3540966 Arginase activity was detected in Escherichia coli cells transformed with the plasmid carrying lambda hARG6 cDNA insert.
GO:0005737 cytoplasm	TAS PMID:3540966 Molecular cloning and nucleotide sequence of cDNA for human ...	KEEP AS NON CORE	Summary: Traceable-author statement of cytoplasmic (liver) arginase localization. Reason: Correct but general; cytosol (GO:0005829) is the more precise term. Retained as a valid broader localization. Supporting Evidence: PMID:21728378 Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney.
GO:0006527 L-arginine catabolic process	TAS PMID:3540966 Molecular cloning and nucleotide sequence of cDNA for human ...	ACCEPT	Summary: Traceable-author statement of ARG1's role in L-arginine catabolism (the terminal urea-cycle step) from the original cloning paper. Reason: Core biological process. ARG1 hydrolyzes L-arginine as the last step of the urea cycle. Duplicate of the IMP L-arginine catabolic process annotation, which is acceptable. Supporting Evidence: PMID:3540966 Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle in the liver of ureotelic animals.

Core Functions

Catalyzes the terminal step of the urea cycle - the manganese-dependent hydrolysis of L-arginine to L-ornithine and urea - regenerating ornithine to close the cycle and releasing the urea that is excreted for nitrogen disposal.

Molecular Function:

arginase activity

Directly Involved In:

urea cycle

Cellular Locations:

cytosol

Supporting Evidence:

PMID:17562323
Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea.

Requires a binuclear manganese cluster (two Mn(2+) ions per subunit) for catalytic activity; manganese binding is an essential cofactor requirement of the arginase active site.

Molecular Function:

arginase activity

Cellular Locations:

cytosol

Supporting Evidence:

PMID:16141327
The ultrahigh-resolution structure of the human arginase I-ABH complex yields an unprecedented view of the binuclear manganese cluster

Breaks down L-arginine (L-arginine catabolic process); loss of this activity in ARG1 causes hyperargininemia/argininemia, a urea cycle disorder.

Molecular Function:

arginase activity

Directly Involved In:

L-arginine catabolic process

Cellular Locations:

cytosol

Supporting Evidence:

PMID:22959135
It is caused by the deficient activity of the enzyme arginase I, encoded by the gene ARG1.

References

GO_REF:0000002

Gene Ontology annotation through association of InterPro records with GO terms

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000041

Gene Ontology annotation based on UniPathway vocabulary mapping

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

GO_REF:0000107

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara

GO_REF:0000117

Electronic Gene Ontology annotations created by ARBA machine learning models

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods

PMID:15546957

Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.

Arginase I is constitutively expressed only in granulocytes among human leukocytes and is localized in azurophil granules, constituting an antimicrobial effector pathway via arginine depletion in the phagolysosome.

"arginase I is localized in azurophil granules of neutrophils and constitutes a novel antimicrobial effector pathway, likely through arginine depletion in the phagolysosome"

PMID:16141327

Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response.

The 1.29-A structure reveals the binuclear manganese cluster of human arginase I and the structural basis of catalysis and inhibition.

"The ultrahigh-resolution structure of the human arginase I-ABH complex yields an unprecedented view of the binuclear manganese cluster"

PMID:16709924

Suppression of T-cell functions by human granulocyte arginase.

Arginase I released from human granulocytes accumulates extracellularly during inflammation and suppresses T-cell proliferation and cytokine synthesis by depleting arginine, downregulating the CD3-zeta chain.

"This T-cell phenotype is due to arginase-mediated depletion of arginine in the T-cell environment, which leads to CD3zeta chain down-regulation but does not alter T-cell viability"

PMID:17562323

Expression, purification, assay, and crystal structure of perdeuterated human arginase I.

Human arginase I is a manganese metalloenzyme that catalyzes hydrolysis of L-arginine to L-ornithine and urea, confirmed by assay and X-ray structure.

"Arginase is a manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to yield l-ornithine and urea."

PMID:21630459

Proteomic characterization of the human sperm nucleus.

A large-scale proteomic catalog identified 403 proteins in isolated human sperm nuclei; ARG1 is one large-scale MS detection, not a targeted study of nuclear arginase function.

"403 different proteins have been identified from the isolated sperm nuclei"

PMID:21728378

Binding of alpha,alpha-disubstituted amino acids to arginase suggests new avenues for inhibitor design.

Arginase is a binuclear manganese metalloenzyme that hydrolyzes L-arginine to L-ornithine and urea; arginase I is cytosolic and predominantly hepatic, whereas arginase II is mitochondrial.

"Arginase I is a cytosolic enzyme found predominantly in the liver, and arginase II is a mitochondrial enzyme found at highest concentrations in the kidney."

PMID:22959135

Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes.

Hyperargininemia is caused by deficient arginase I activity encoded by ARG1; the R308 residue is important for assembly of the ARG1 homotrimer.

"Our study reinforced the role of Arg308 residue for assembly of the ARG1 homotrimer."

PMID:28813417

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

This study identifies CMTM6 as a regulator of PD-L1 cell-surface expression; ARG1 appears only as a mass-spectrometry co-precipitant of CMTM6, providing no functional evidence for an ARG1-specific role.

"CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression."

PMID:3540966

Molecular cloning and nucleotide sequence of cDNA for human liver arginase.

Human liver arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle; cloned cDNA conferred arginase activity, and inherited deficiency causes argininemia.

"Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle in the liver of ureotelic animals."

Reactome:R-HSA-6798749

Exocytosis of specific granule lumen proteins

Reactome:R-HSA-6798751

Exocytosis of azurophil granule lumen proteins

Reactome:R-HSA-70569

arginine + H2O => ornithine + urea [ARG1]

Reactome:R-HSA-9956512

ARG1 variants don't synthesize urea and ornithine

Reactome:R-HSA-9959871

ARG1 gene expression

Suggested Experiments

Experiment: Structure-guided kinetic characterization of clinically observed missense variants (e.g. those affecting the Mn-binding residues or the R308 trimerization interface) to correlate residual arginase activity with argininemia phenotype severity.

Hypothesis: Argininemia severity is determined by residual arginase activity, which depends on how a given missense variant perturbs the Mn-binding active site or the R308 trimerization interface.

Experiment: Quantitative measurement of local arginine depletion and downstream T-cell CD3-zeta levels using ARG1-deficient versus wild-type human neutrophils to dissect the enzymatic basis of the immunosuppressive effect.

Hypothesis: The immunosuppressive effect of neutrophil ARG1 is entirely due to enzymatic depletion of extracellular L-arginine.

Deep Research

Falcon

(ARG1-deep-research-falcon.md)

Comprehensive Research Report on Human ARG1 (Arginase-1, P05089) Falcon Edison Scientific Literature 42 citations 2 artifacts 2026-07-05T14:03:07.024822

Edison artifact artifact-00 (text/markdown)

Edison artifact artifact-01 (text/markdown)

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report on Human ARG1 (Arginase-1, P05089)

1. Gene and Protein Identity

Human Arginase-1 (ARG1) is encoded by the ARG1 gene located on chromosome 6q23, consisting of 8 exons (nteli2024argininemiapathophysiologyand pages 8-10). The protein is classified as EC 3.5.3.1 and is also known as liver-type arginase or type I arginase (anakha2022humanarginase1 pages 1-3). ARG1 belongs to the ureohydrolase/arginase protein family and contains a characteristic ureohydrolase domain with a manganese-binding site. Over 43 pathogenic mutations have been identified in the ARG1 gene, distributed across exons and splice sites (nteli2024argininemiapathophysiologyand pages 8-10). In humans, three splice variants exist: isoform 1 (322 amino acids), mainly expressed in the liver; isoform 2 (330 amino acids), expressed in immune cells and erythrocytes; and isoform 3, whose function remains undefined (cane2025therolesof pages 1-2).

The following table summarizes key properties of ARG1:

Property	Summary
Gene name	ARG1 (arginase 1) (OpenTargets Search: -ARG1, nteli2024argininemiapathophysiologyand pages 2-3)
UniProt accession	P05089 (user-provided target specification)
EC number	EC 3.5.3.1 (anakha2022humanarginase1 pages 1-3)
Protein mass	Mature enzyme is described as a ~105 kDa homotrimer with ~35 kDa subunits; some reviews also report ~130 kDa total trimer mass depending on construct/annotation conventions (anakha2022humanarginase1 pages 1-3, palte2021cryoemstructuresof pages 1-2, li2022reviewofarginase pages 3-5)
Quaternary structure	Homotrimeric metalloenzyme; trimerization is required for full catalytic activity, and monomerization causes major loss of activity (>90%) (anakha2022humanarginase1 pages 1-3, dechenne2025examiningarginase1trimerization pages 7-9, dechenne2025examiningarginase1trimerization pages 1-2)
Subcellular localization	Cytosol (especially hepatocyte cytosol); distinct from mitochondrial ARG2 (clemente2020arginaseasa pages 1-3, anakha2022humanarginase1 pages 1-3, cane2025therolesof pages 2-3)
Primary tissue expression	Predominantly liver, especially periportal/zone 1 hepatocytes; also detected in erythrocytes, vasculature, and immune cells such as M2-like macrophages (nteli2024argininemiapathophysiologyand pages 2-3, zhu2026ureacycledysregulation pages 4-5, cane2025therolesof pages 1-2)
Catalytic cofactor	Binuclear Mn2+ center with two manganese ions in each active site, bridged by hydroxide/water during catalysis (clemente2020arginaseasa pages 1-3, li2022reviewofarginase pages 3-5, palte2021cryoemstructuresof pages 1-2)
Substrate	L-arginine is the physiological substrate; wild-type human ARG1 does not efficiently hydrolyze agmatine (clemente2020arginaseasa pages 1-3, orellana2022newinsightsinto pages 1-2, orellana2022newinsightsinto pages 6-7, orellana2022newinsightsinto pages 2-4)
Products	L-ornithine + urea (anakha2022humanarginase1 pages 1-3, clemente2020arginaseasa pages 1-3, nteli2024argininemiapathophysiologyand pages 2-3)
Km value	Km ~3.3 mM for ARG1 under the reported assay conditions (pH 7.4) (clemente2020arginaseasa pages 3-6)
Reaction catalyzed	Hydrolysis of L-arginine to L-ornithine and urea; final step of the hepatic urea cycle and a key branchpoint in arginine metabolism (anakha2022humanarginase1 pages 1-3, nteli2024argininemiapathophysiologyand pages 2-3, clemente2020arginaseasa pages 1-3)
Key disease associations	Arginase deficiency / argininemia (strong genetic disease association), plus links to cancer immune suppression/tumor microenvironment, and Open Targets associations with hereditary disease, type 2 diabetes mellitus, and obesity disorder (anakha2022humanarginase1 pages 3-4, nteli2024argininemiapathophysiologyand pages 5-7, nteli2024argininemiapathophysiologyand pages 2-3, marzetaassas2024pathophysiologyofarginases pages 13-14, grzybowski2025metabolomicreprogrammingof pages 2-3, OpenTargets Search: -ARG1)

Table: This table summarizes core biochemical, structural, localization, and disease-related properties of human Arginase-1 (ARG1/P05089). It is useful as a compact reference for functional annotation and interpretation of disease relevance.

2. Enzymatic Function and Catalytic Mechanism

2.1 Primary Reaction

ARG1 is a metalloenzyme that catalyzes the hydrolysis of L-arginine to produce L-ornithine and urea (anakha2022humanarginase1 pages 1-3, clemente2020arginaseasa pages 1-3). This reaction represents the fifth and final step of the hepatic urea cycle, completing the conversion of toxic ammonia to urea for renal excretion (nteli2024argininemiapathophysiologyand pages 2-3). The enzyme exhibits a Km of approximately 3.3 mM and a Vmax of 34 nmol·min⁻¹·mg⁻¹ at pH 7.4 (clemente2020arginaseasa pages 3-6).

2.2 Catalytic Mechanism

The catalytic mechanism of ARG1 depends on a binuclear manganese (Mn²⁺) cluster located at the active site. Two Mn²⁺ ions are positioned approximately 3.3 Å apart and are bridged by a hydroxide ion (clemente2020arginaseasa pages 1-3, palte2021cryoemstructuresof pages 1-2). During catalysis, the Mn²⁺ ions form a metal-bound hydroxide from a water molecule, which serves as the nucleophile that attacks the guanidinium carbon of L-arginine (anakha2022humanarginase1 pages 1-3, li2022reviewofarginase pages 3-5). This nucleophilic attack generates a tetrahedral intermediate that is stabilized by the binuclear Mn²⁺ center. Specific amino acid residues, including Asp128, provide stabilization through hydrogen bonding. A histidine residue (His-141 in ARG1) facilitates proton shuttling from bulk solvent to the active site, enabling L-ornithine dissociation (li2022reviewofarginase pages 3-5, clemente2020arginaseasa pages 3-6). The tetrahedral intermediate subsequently collapses to release the products L-ornithine and urea, and the metal ions recycle by rebinding water molecules for subsequent catalytic cycles (li2022reviewofarginase pages 3-5). Although Mn²⁺ is the preferred cofactor, Ni²⁺, Co²⁺, and Fe²⁺ can also activate the enzyme (li2022reviewofarginase pages 3-5).

2.3 Substrate Specificity

Wild-type human ARG1 is highly specific for L-arginine as its physiological substrate and does not efficiently hydrolyze agmatine (a decarboxylated arginine analog) (orellana2022newinsightsinto pages 1-2, orellana2022newinsightsinto pages 2-4). This specificity is determined by two critical loops at the entrance of the active site: Loop A (residues I129–L140) and Loop B (residues D181–P184) (orellana2022newinsightsinto pages 1-2). Loop A contains residues N130, S137, and N139 that specifically stabilize the α-carboxyl group of arginine through hydrogen bonding; since agmatine lacks this carboxyl group, these residues create a selectivity barrier (orellana2022newinsightsinto pages 2-4). Loop B interacts with the α-amino group of arginine and serves as a structural determinant of substrate affinity (orellana2022newinsightsinto pages 1-2, orellana2022newinsightsinto pages 11-12). Mutagenesis studies have demonstrated that engineered changes to Loop A (I129T/N130Y/T131A with deletion of P132-T134) can completely switch the enzyme's specificity from arginine to agmatine (orellana2022newinsightsinto pages 12-14, orellana2022newinsightsinto pages 6-7). Similarly, double mutations D181T/V182E in Loop B result in a 20-fold increase in Km for arginine, confirming these loops as the primary determinants of substrate recognition (orellana2022newinsightsinto pages 7-9).

3. Quaternary Structure and Assembly

ARG1 functions as an obligate homotrimer. Each monomer is approximately 35 kDa and adopts an α/β fold with a central β-sheet flanked by α-helices (clemente2020arginaseasa pages 3-6, palte2021cryoemstructuresof pages 1-2). The trimeric complex has a total molecular weight of approximately 105–130 kDa, depending on the construct and measurement method (anakha2022humanarginase1 pages 1-3, li2022reviewofarginase pages 3-5). Each monomer contains a separate active site with its own binuclear Mn²⁺ center (li2022reviewofarginase pages 3-5).

Critically, only the trimeric form of ARG1 is catalytically active. Production of a monomeric form results in greater than 90% loss of enzymatic activity (dechenne2025examiningarginase1trimerization pages 7-9, dechenne2025examiningarginase1trimerization pages 1-2). The trimeric interface involves two α-helices and a C-terminal tail, with five key amino acids (M200, D204, R255, E256, R308) being essential for trimerization. Mutation of R255 to alanine produces a fully monomeric, inactive enzyme (dechenne2025examiningarginase1trimerization pages 7-9, dechenne2025examiningarginase1trimerization pages 2-5). The active site extends approximately 15 Å deep and terminates at the two catalytic manganese ions (palte2021cryoemstructuresof pages 1-2). This structural dependence on trimerization has been exploited as a novel drug target—phenylglyoxal covalently modifies a critical arginine residue (R205) within the allosteric trimerization pocket, disrupting oligomerization and partially reducing enzymatic activity (dechenne2025examiningarginase1trimerization pages 9-10, dechenne2025examiningarginase1trimerization pages 1-2). Cryo-EM structures of inhibitory antibodies complexed with ARG1 have been resolved at local resolutions of 3.5 Å or better, revealing both orthosteric and allosteric mechanisms of inhibition (palte2021cryoemstructuresof pages 1-2).

4. Subcellular Localization and Tissue Distribution

ARG1 is a cytosolic enzyme, in contrast to arginase 2 (ARG2), which localizes to the mitochondrial matrix (clemente2020arginaseasa pages 1-3, anakha2022humanarginase1 pages 1-3, cane2025therolesof pages 2-3). Its primary site of expression is the liver, where it is highly expressed in periportal (zone 1) hepatocytes—the region where blood arriving via the portal vein is rich in oxygen and amino acids, and where urea cycle enzymes are most active for ammonia detoxification (zhu2026ureacycledysregulation pages 4-5). Beyond the liver, ARG1 is also detected in erythrocytes, vascular endothelial cells, and immune cells, including M2-polarized macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs) (nteli2024argininemiapathophysiologyand pages 2-3, cane2025therolesof pages 1-2, cane2025therolesof pages 2-3). Neutrophils store ARG1 in gelatinase (tertiary) granules, from which it can be released upon degranulation (nteli2024argininemiapathophysiologyand pages 2-3).

5. Biochemical Pathways

5.1 The Urea Cycle

In hepatocytes, ARG1 catalyzes the final step of the urea cycle by hydrolyzing L-arginine to L-ornithine and urea. The ornithine product is recycled into the urea cycle via ornithine transcarbamylase (OTC) in the mitochondria, while urea is transported through the bloodstream to the kidneys for excretion (nteli2024argininemiapathophysiologyand pages 2-3, clemente2020arginaseasa pages 1-3). This pathway is the primary route for nitrogen disposal in mammals, converting highly toxic ammonia to the relatively benign molecule urea.

5.2 Downstream Metabolic Pathways

The L-ornithine produced by ARG1 serves as a critical metabolic branch-point feeding into two major downstream pathways, summarized in the following table:

Pathway/Step	Enzyme(s)	Substrate(s)	Product(s)	Biological significance
ARG1 core reaction	ARG1 (arginase-1)	L-arginine + H2O	L-ornithine + urea	Final cytosolic step of the hepatic urea cycle; detoxifies ammonia by enabling urea excretion and generates ornithine as a branch-point metabolite for downstream biosynthesis (clemente2020arginaseasa pages 1-3, nteli2024argininemiapathophysiologyand pages 2-3)
Polyamine pathway: ornithine to putrescine	ODC/ODC1 (ornithine decarboxylase)	L-ornithine	Putrescine	First rate-limiting step in polyamine synthesis; supports cell proliferation, repair, and metabolic reprogramming in immune and tumor contexts (li2026arg1polyamineaxiscelltypespecific pages 1-2, li2026arg1polyamineaxiscelltypespecific pages 2-3, xu2026molecularmechanismsand pages 3-4)
Polyamine pathway: putrescine to spermidine	SRM (spermidine synthase)	Putrescine	Spermidine	Builds polyamine pools that support proliferation, differentiation, mitochondrial fitness, and epigenetic regulation (cane2025therolesof pages 2-3)
Polyamine pathway: spermidine to spermine	SMS (spermine synthase)	Spermidine	Spermine	Extends polyamine pathway to support cell growth, migration, differentiation, and broader anabolic programs (cane2025therolesof pages 2-3)
Proline/collagen pathway: ornithine transamination	OAT (ornithine aminotransferase)	L-ornithine	L-glutamate 5-semialdehyde / P5C precursor	Directs ARG1-derived ornithine toward proline biosynthesis, linking arginine catabolism to tissue repair, extracellular matrix production, and fibrosis/collagen programs (li2026arg1polyamineaxiscelltypespecific pages 1-2, li2026arg1polyamineaxiscelltypespecific pages 2-3, karadima2025argininemetabolismin pages 1-2)
Proline/collagen pathway: P5C to proline	PYCR	P5C (1-pyrroline-5-carboxylate)	Proline	Supplies proline for collagen synthesis and extracellular matrix deposition, especially in wound healing, tissue remodeling, and reparative macrophage programs (cane2025therolesof pages 2-3)
Competing arginine-utilization pathway	NOS (nitric oxide synthase; iNOS/eNOS/nNOS)	L-arginine	Nitric oxide (NO) + citrulline	Competes directly with ARG1 for L-arginine. NOS supports antimicrobial defense, vasodilation, and signaling, whereas ARG1 diverts arginine toward ornithine/polyamine/proline production. Although NOS has higher substrate affinity, arginase has a 10^3-10^4 higher Vmax, making ARG1 a powerful competitor for the shared substrate pool (li2026arg1polyamineaxiscelltypespecific pages 1-2, cane2025therolesof pages 2-3, li2026arg1polyamineaxiscelltypespecific pages 2-3, clemente2020arginaseasa pages 3-6)

Table: This table summarizes the main biochemical fates of ARG1-generated ornithine and the competing NOS branch from arginine. It is useful for understanding how ARG1 links the urea cycle to polyamine synthesis, proline/collagen production, and nitric-oxide-related signaling.

First, L-ornithine enters the polyamine synthesis pathway, where ornithine decarboxylase (ODC/ODC1) converts it to putrescine in the rate-limiting first step. Putrescine is then sequentially converted to spermidine by spermidine synthase (SRM) and to spermine by spermine synthase (SMS). These polyamines are essential for cell proliferation, migration, epigenetic regulation, and differentiation (li2026arg1polyamineaxiscelltypespecific pages 1-2, cane2025therolesof pages 2-3, li2026arg1polyamineaxiscelltypespecific pages 2-3).

Second, L-ornithine can be transaminated by ornithine aminotransferase (OAT) to produce L-glutamate 5-semialdehyde, which is further converted to 1-pyrroline-5-carboxylate (P5C) and then to L-proline by pyrroline-5-carboxylate reductase (PYCR). Proline is a critical building block for collagen and extracellular matrix deposition, linking ARG1 activity to tissue repair and fibrosis (cane2025therolesof pages 2-3, karadima2025argininemetabolismin pages 1-2).

5.3 Competition with Nitric Oxide Synthase

A critically important aspect of ARG1 biology is its competition with nitric oxide synthase (NOS) for the shared substrate L-arginine (li2026arg1polyamineaxiscelltypespecific pages 1-2, li2026arg1polyamineaxiscelltypespecific pages 2-3). While ARG1 hydrolyzes L-arginine to ornithine and urea, NOS enzymes (iNOS, eNOS, nNOS) oxidize L-arginine to produce nitric oxide (NO) and citrulline. Although NOS has a higher substrate affinity (lower Km), ARG1 possesses a 10³–10⁴ times higher Vmax, making it a highly effective competitor that can deplete the L-arginine pool available for NO production (clemente2020arginaseasa pages 3-6). This competition has multiple downstream consequences: decreased L-arginine availability for NOS, potential uncoupling of NOS to produce harmful superoxide and peroxynitrite, and repression of NOS2 protein translation and stability (cane2025therolesof pages 2-3). The balance between the ARG1 and NOS pathways fundamentally determines whether cellular arginine metabolism favors immune suppression and tissue repair (via ornithine/polyamines/proline) or pro-inflammatory/antimicrobial responses (via NO) (li2026arg1polyamineaxiscelltypespecific pages 1-2, li2026arg1polyamineaxiscelltypespecific pages 2-3, karadima2025argininemetabolismin pages 1-2).

6. Role in Immune Regulation

6.1 Macrophage Polarization

ARG1 is a defining marker and functional effector of M2 (alternatively activated, anti-inflammatory) macrophages. Its expression is induced by T helper 2 (Th2) cytokines IL-4 and IL-13 through JAK-STAT6 signaling, and by anti-inflammatory cytokines IL-10 and TGFβ. Pro-inflammatory cytokines IL-6 and TNF can also upregulate ARG1 through STAT3-dependent mechanisms (li2026arg1polyamineaxiscelltypespecific pages 4-5, pan2025harnessingaminoacid pages 8-10, cane2025therolesof pages 3-4). In macrophages, ARG1-derived ornithine fuels polyamine synthesis via ODC, promoting M2 polarization through enhanced mitochondrial oxidative phosphorylation, epigenetic modifications, autophagy, and efferocytosis (li2026arg1polyamineaxiscelltypespecific pages 4-5, pan2025harnessingaminoacid pages 8-10, li2026arg1polyamineaxiscelltypespecific pages 2-3). The ARG1/iNOS competitive axis represents a metabolic switch: in M1 pro-inflammatory macrophages, iNOS predominates to produce NO, whereas in M2 macrophages, ARG1 predominates to produce ornithine and polyamines (li2026arg1polyamineaxiscelltypespecific pages 5-7).

6.2 T Cell Suppression

Myeloid cell-derived ARG1 represents a major immunosuppressive mechanism. By depleting extracellular L-arginine, ARG1 impairs T cell activation and proliferation through downregulation of the T cell receptor CD3ζ chain (pan2025harnessingaminoacid pages 8-10, grzybowski2025metabolomicreprogrammingof pages 2-3). This mechanism is operative in tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and tumor-associated neutrophils (TANs), all of which upregulate ARG1 to create an immunosuppressive tumor microenvironment (li2026arg1polyamineaxiscelltypespecific pages 4-5, li2026arg1polyamineaxiscelltypespecific pages 5-7, li2026arg1polyamineaxiscelltypespecific pages 3-4, cane2025therolesof pages 17-17). In pancreatic cancer, genetic inactivation of ARG1 in macrophages delays formation of invasive disease while increasing CD8⁺ T cell infiltration, directly demonstrating that ARG1 functions as more than a mere polarization marker—it actively drives immune suppression (li2026arg1polyamineaxiscelltypespecific pages 3-4). Lactic acid in the tumor microenvironment further induces ARG1 expression in TAMs via hypoxia-inducible factor stabilization (cane2025therolesof pages 3-4).

7. Disease Associations

7.1 Argininemia (Arginase Deficiency)

Loss-of-function mutations in ARG1 cause argininemia (arginase-1 deficiency, OMIM), a rare autosomal recessive urea cycle disorder (anakha2022humanarginase1 pages 1-3, nteli2024argininemiapathophysiologyand pages 2-3). The disease is characterized by severely elevated plasma arginine (>300 µmol/L) and erythrocyte arginase activity below 1% of normal (nteli2024argininemiapathophysiologyand pages 5-7). Clinical manifestations include progressive spastic diplegia/paraparesis (the hallmark symptom beginning in the first decade of life), cognitive deficits, intellectual disability, seizures (in 60–75% of patients), and hepatic dysfunction ranging from neonatal jaundice to cirrhosis (nteli2024argininemiapathophysiologyand pages 2-3). The pathophysiology involves direct neurotoxicity of elevated arginine, accumulation of neurotoxic and epileptogenic guanidino compounds, excessive NO production leading to endothelial abnormalities, and decreased ornithine levels impairing oligodendrocyte function and causing dysmyelination (nteli2024argininemiapathophysiologyand pages 3-5). Current treatments include dietary protein restriction with essential amino acid supplementation, nitrogen scavengers (benzoate, phenylbutyrate), and liver transplantation, which effectively normalizes arginine and ammonia levels (nteli2024argininemiapathophysiologyand pages 5-7). Pegzilarginase (Co-rhARG1-PEG), a PEGylated cobalt-substituted recombinant human arginase 1 with improved stability and half-life, has received FDA Breakthrough Therapy Designation and has shown efficacy in reducing plasma arginine in approximately 50% of patients (anakha2022humanarginase1 pages 3-4). OpenTargets data confirms strong disease-target associations between ARG1 and arginase deficiency (score 0.78) and argininemia (score 0.80), as well as associations with hereditary disease (score 0.86), type 2 diabetes mellitus (score 0.44), and obesity disorder (score 0.36) (OpenTargets Search: -ARG1).

7.2 Cancer and Immunotherapy

ARG1 is increasingly recognized as a therapeutic target in cancer immunotherapy. Elevated ARG1 activity in the tumor microenvironment correlates with poor prognosis across multiple cancer types by promoting immune evasion through L-arginine depletion and polyamine-mediated tumor cell proliferation (grzybowski2025metabolomicreprogrammingof pages 2-3). The arginase inhibitor CB-1158 (INCB001158/numidargistat), with an IC₅₀ of 98 nM for ARG1, was evaluated in a first-in-human phase 1 clinical trial (NCT02903914) in patients with advanced solid tumors. While generally well tolerated and showing pharmacodynamic activity (dose-dependent increases in plasma arginine), the limited antitumor activity observed as monotherapy or in combination with pembrolizumab suggested that the role of arginine depletion in cancer is multifaceted (marzetaassas2024pathophysiologyofarginases pages 13-14, marzetaassas2024pathophysiologyofarginases pages 11-13). A key limitation of CB-1158 is its restricted intracellular penetration, affecting primarily extracellular ARG1 (grzybowski2025metabolomicreprogrammingof pages 2-3). The next-generation dual ARG1/ARG2 inhibitor OATD-02 (IC₅₀ 20–48 nM) was designed to overcome this limitation by effectively inhibiting both extracellular and intracellular arginases (marzetaassas2024pathophysiologyofarginases pages 13-14, borek2023arginase12inhibitor pages 1-1). Preclinical studies show that OATD-02 restores intratumoral L-arginine while depleting polyamines, leading to increased CD8⁺ T cell infiltration, enhanced T cell activation, and improved response to anti-PD-1 checkpoint blockade (grzybowski2025metabolomicreprogrammingof pages 1-2). OATD-02 is currently undergoing clinical evaluation in a phase I/II trial (NCT05759923) (grzybowski2025metabolomicreprogrammingof pages 1-2).

8. Summary

Human ARG1 is a cytosolic, homotrimeric, binuclear manganese metalloenzyme that catalyzes the final step of the urea cycle—the hydrolysis of L-arginine to L-ornithine and urea. Its enzymatic activity is strictly dependent on trimeric assembly and the presence of two Mn²⁺ ions at each active site. The enzyme is highly specific for L-arginine, with substrate recognition determined by two structural loops (Loop A and Loop B) at the active site entrance. ARG1 is predominantly expressed in liver periportal hepatocytes, where it functions in nitrogen detoxification, but is also expressed in immune cells (M2 macrophages, MDSCs, neutrophils), where it serves as a key immunomodulatory enzyme. Through competition with NOS for L-arginine and through production of ornithine-derived polyamines and proline, ARG1 occupies a critical metabolic branch-point linking nitrogen metabolism, immune regulation, tissue repair, and cell proliferation. Loss of ARG1 function causes the rare metabolic disorder argininemia, while overexpression in the tumor microenvironment contributes to immune evasion in cancer, making ARG1 an active target for both enzyme replacement therapy and immunotherapeutic inhibition.

References

(nteli2024argininemiapathophysiologyand pages 8-10): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 4 citations.
(anakha2022humanarginase1 pages 1-3): J. Anakha, Priyanka S. Kawathe, Sayantap Datta, Snehal Sainath Jawalekar, Uttam Chand Banerjee, and Abhay H. Pande. Human arginase 1, a jack of all trades? 3 Biotech, Sep 2022. URL: https://doi.org/10.1007/s13205-022-03326-9, doi:10.1007/s13205-022-03326-9. This article has 18 citations and is from a peer-reviewed journal.
(cane2025therolesof pages 1-2): Stefania Canè, Roger Geiger, and Vincenzo Bronte. The roles of arginases and arginine in immunity. Nature reviews. Immunology, Oct 2025. URL: https://doi.org/10.1038/s41577-024-01098-2, doi:10.1038/s41577-024-01098-2. This article has 118 citations.
(OpenTargets Search: -ARG1): Open Targets Query (-ARG1, 13 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(nteli2024argininemiapathophysiologyand pages 2-3): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 4 citations.
(palte2021cryoemstructuresof pages 1-2): Rachel L. Palte, Veronica Juan, Yacob Gomez-Llorente, Marc Andre Bailly, Kalyan Chakravarthy, Xun Chen, Daniel Cipriano, Ghassan N. Fayad, Laurence Fayadat-Dilman, Symon Gathiaka, Heiko Greb, Brian Hall, Mas Handa, Mark Hsieh, Esther Kofman, Heping Lin, J. Richard Miller, Nhung Nguyen, Jennifer O’Neil, Hussam Shaheen, Eric Sterner, Corey Strickland, Angie Sun, Shane Taremi, and Giovanna Scapin. Cryo-em structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action. Communications Biology, Jul 2021. URL: https://doi.org/10.1038/s42003-021-02444-z, doi:10.1038/s42003-021-02444-z. This article has 11 citations and is from a peer-reviewed journal.
(li2022reviewofarginase pages 3-5): Mengli Li, Jiufu Qin, Kai Xiong, Bo Jiang, and Tao Zhang. Review of arginase as a promising biocatalyst: characteristics, preparation, applications and future challenges. Critical Reviews in Biotechnology, 42:651-667, Oct 2022. URL: https://doi.org/10.1080/07388551.2021.1947962, doi:10.1080/07388551.2021.1947962. This article has 23 citations and is from a peer-reviewed journal.
(dechenne2025examiningarginase1trimerization pages 7-9): Juhans Dechenne, Magdalena Wierzbicka, Reda Krimou, Asia El Aakchioui, Julia Malo Pueyo, Joris Messens, Marianne Fillet, Quentin Spillier, and Raphaël Frédérick. Examining arginase-1 trimerization uncovers a promising allosteric site for inhibition. Journal of medicinal chemistry, 68:1433-1445, Jan 2025. URL: https://doi.org/10.1021/acs.jmedchem.4c01993, doi:10.1021/acs.jmedchem.4c01993. This article has 3 citations and is from a highest quality peer-reviewed journal.
(dechenne2025examiningarginase1trimerization pages 1-2): Juhans Dechenne, Magdalena Wierzbicka, Reda Krimou, Asia El Aakchioui, Julia Malo Pueyo, Joris Messens, Marianne Fillet, Quentin Spillier, and Raphaël Frédérick. Examining arginase-1 trimerization uncovers a promising allosteric site for inhibition. Journal of medicinal chemistry, 68:1433-1445, Jan 2025. URL: https://doi.org/10.1021/acs.jmedchem.4c01993, doi:10.1021/acs.jmedchem.4c01993. This article has 3 citations and is from a highest quality peer-reviewed journal.
(clemente2020arginaseasa pages 1-3): Gonçalo S. Clemente, Aren van Waarde, Inês F. Antunes, Alexander Dömling, and Philip H. Elsinga. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. International Journal of Molecular Sciences, 21:5291, Jul 2020. URL: https://doi.org/10.3390/ijms21155291, doi:10.3390/ijms21155291. This article has 140 citations.
(cane2025therolesof pages 2-3): Stefania Canè, Roger Geiger, and Vincenzo Bronte. The roles of arginases and arginine in immunity. Nature reviews. Immunology, Oct 2025. URL: https://doi.org/10.1038/s41577-024-01098-2, doi:10.1038/s41577-024-01098-2. This article has 118 citations.
(zhu2026ureacycledysregulation pages 4-5): Boying Zhu, Chaoyang Wang, Peng Liu, Zhifeng Qu, Ran Qi, Shengjiang Chen, and Huanzhang Niu. Urea cycle dysregulation and arginine pathways in the pathogenesis of nafld and nash (review). International Journal of Molecular Medicine, 58:1-21, Jun 2026. URL: https://doi.org/10.3892/ijmm.2026.5886, doi:10.3892/ijmm.2026.5886. This article has 0 citations and is from a peer-reviewed journal.
(orellana2022newinsightsinto pages 1-2): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(orellana2022newinsightsinto pages 6-7): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(orellana2022newinsightsinto pages 2-4): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(clemente2020arginaseasa pages 3-6): Gonçalo S. Clemente, Aren van Waarde, Inês F. Antunes, Alexander Dömling, and Philip H. Elsinga. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. International Journal of Molecular Sciences, 21:5291, Jul 2020. URL: https://doi.org/10.3390/ijms21155291, doi:10.3390/ijms21155291. This article has 140 citations.
(anakha2022humanarginase1 pages 3-4): J. Anakha, Priyanka S. Kawathe, Sayantap Datta, Snehal Sainath Jawalekar, Uttam Chand Banerjee, and Abhay H. Pande. Human arginase 1, a jack of all trades? 3 Biotech, Sep 2022. URL: https://doi.org/10.1007/s13205-022-03326-9, doi:10.1007/s13205-022-03326-9. This article has 18 citations and is from a peer-reviewed journal.
(nteli2024argininemiapathophysiologyand pages 5-7): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 4 citations.
(marzetaassas2024pathophysiologyofarginases pages 13-14): Patrycja Marzęta-Assas, Damian Jacenik, and Zbigniew Zasłona. Pathophysiology of arginases in cancer and efforts in their pharmacological inhibition. International Journal of Molecular Sciences, 25:9782, Sep 2024. URL: https://doi.org/10.3390/ijms25189782, doi:10.3390/ijms25189782. This article has 17 citations.
(grzybowski2025metabolomicreprogrammingof pages 2-3): Marcin Mikołaj Grzybowski, Yasemin Uçal, Angelika Muchowicz, Tomasz Rejczak, Agnieszka Kikulska, Katarzyna Maria Głuchowska, Małgorzata Szostakowska-Rodzoś, Agnieszka Zagożdżon, Tobias Bausbacher, Agnieszka Tkaczyk, Magdalena Kulma, Paulina Pomper, Michał Mlącki, Adam Konrad Jagielski, Roman Błaszczyk, Carsten Hopf, and Zbigniew Zasłona. Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor oatd-02 boosts anticancer immunity. Scientific Reports, May 2025. URL: https://doi.org/10.1038/s41598-025-03446-1, doi:10.1038/s41598-025-03446-1. This article has 24 citations and is from a peer-reviewed journal.
(orellana2022newinsightsinto pages 11-12): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(orellana2022newinsightsinto pages 12-14): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(orellana2022newinsightsinto pages 7-9): María-Soledad Orellana, Gonzalo A. Jaña, Maximiliano Figueroa, José Martínez-Oyanedel, Fabiola E. Medina, Estefanía Tarifeño-Saldivia, Marcell Gatica, María Ángeles García-Robles, Nelson Carvajal, and Elena Uribe. New insights into the determinants of specificity in human type i arginase: generation of a mutant that is only active with agmatine as substrate. International Journal of Molecular Sciences, 23:6438, Jun 2022. URL: https://doi.org/10.3390/ijms23126438, doi:10.3390/ijms23126438. This article has 2 citations.
(dechenne2025examiningarginase1trimerization pages 2-5): Juhans Dechenne, Magdalena Wierzbicka, Reda Krimou, Asia El Aakchioui, Julia Malo Pueyo, Joris Messens, Marianne Fillet, Quentin Spillier, and Raphaël Frédérick. Examining arginase-1 trimerization uncovers a promising allosteric site for inhibition. Journal of medicinal chemistry, 68:1433-1445, Jan 2025. URL: https://doi.org/10.1021/acs.jmedchem.4c01993, doi:10.1021/acs.jmedchem.4c01993. This article has 3 citations and is from a highest quality peer-reviewed journal.
(dechenne2025examiningarginase1trimerization pages 9-10): Juhans Dechenne, Magdalena Wierzbicka, Reda Krimou, Asia El Aakchioui, Julia Malo Pueyo, Joris Messens, Marianne Fillet, Quentin Spillier, and Raphaël Frédérick. Examining arginase-1 trimerization uncovers a promising allosteric site for inhibition. Journal of medicinal chemistry, 68:1433-1445, Jan 2025. URL: https://doi.org/10.1021/acs.jmedchem.4c01993, doi:10.1021/acs.jmedchem.4c01993. This article has 3 citations and is from a highest quality peer-reviewed journal.
(li2026arg1polyamineaxiscelltypespecific pages 1-2): Lexing Li, Guoyan Zhu, Meng-Zhang Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, and Leilei Liu. Arg1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting. Frontiers in Immunology, Mar 2026. URL: https://doi.org/10.3389/fimmu.2026.1744890, doi:10.3389/fimmu.2026.1744890. This article has 0 citations and is from a peer-reviewed journal.
(li2026arg1polyamineaxiscelltypespecific pages 2-3): Lexing Li, Guoyan Zhu, Meng-Zhang Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, and Leilei Liu. Arg1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting. Frontiers in Immunology, Mar 2026. URL: https://doi.org/10.3389/fimmu.2026.1744890, doi:10.3389/fimmu.2026.1744890. This article has 0 citations and is from a peer-reviewed journal.
(xu2026molecularmechanismsand pages 3-4): Yuhang Xu, Mingxin Yu, Yi Zhang, Yiqing Jiang, Haiyan Zhu, Shujuan He, Guohua Yu, Niannian Li, Shuzhen Liu, and Bin Liu. Molecular mechanisms and therapies for tumor inhibition through the arginine metabolism pathway. Frontiers in Oncology, Feb 2026. URL: https://doi.org/10.3389/fonc.2026.1774392, doi:10.3389/fonc.2026.1774392. This article has 0 citations.
(karadima2025argininemetabolismin pages 1-2): Eleftheria Karadima, Triantafyllos Chavakis, and Vasileia Ismini Alexaki. Arginine metabolism in myeloid cells in health and disease. Seminars in Immunopathology, Jan 2025. URL: https://doi.org/10.1007/s00281-025-01038-9, doi:10.1007/s00281-025-01038-9. This article has 67 citations and is from a domain leading peer-reviewed journal.
(li2026arg1polyamineaxiscelltypespecific pages 4-5): Lexing Li, Guoyan Zhu, Meng-Zhang Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, and Leilei Liu. Arg1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting. Frontiers in Immunology, Mar 2026. URL: https://doi.org/10.3389/fimmu.2026.1744890, doi:10.3389/fimmu.2026.1744890. This article has 0 citations and is from a peer-reviewed journal.
(pan2025harnessingaminoacid pages 8-10): Jiongli Pan, Yi Lin, Xinyuan Liu, Xiaozhen Zhang, Tingbo Liang, and Xueli Bai. Harnessing amino acid pathways to influence myeloid cell function in tumor immunity. Molecular Medicine, Feb 2025. URL: https://doi.org/10.1186/s10020-025-01099-4, doi:10.1186/s10020-025-01099-4. This article has 18 citations and is from a peer-reviewed journal.
(cane2025therolesof pages 3-4): Stefania Canè, Roger Geiger, and Vincenzo Bronte. The roles of arginases and arginine in immunity. Nature reviews. Immunology, Oct 2025. URL: https://doi.org/10.1038/s41577-024-01098-2, doi:10.1038/s41577-024-01098-2. This article has 118 citations.
(li2026arg1polyamineaxiscelltypespecific pages 5-7): Lexing Li, Guoyan Zhu, Meng-Zhang Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, and Leilei Liu. Arg1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting. Frontiers in Immunology, Mar 2026. URL: https://doi.org/10.3389/fimmu.2026.1744890, doi:10.3389/fimmu.2026.1744890. This article has 0 citations and is from a peer-reviewed journal.
(li2026arg1polyamineaxiscelltypespecific pages 3-4): Lexing Li, Guoyan Zhu, Meng-Zhang Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, and Leilei Liu. Arg1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting. Frontiers in Immunology, Mar 2026. URL: https://doi.org/10.3389/fimmu.2026.1744890, doi:10.3389/fimmu.2026.1744890. This article has 0 citations and is from a peer-reviewed journal.
(cane2025therolesof pages 17-17): Stefania Canè, Roger Geiger, and Vincenzo Bronte. The roles of arginases and arginine in immunity. Nature reviews. Immunology, Oct 2025. URL: https://doi.org/10.1038/s41577-024-01098-2, doi:10.1038/s41577-024-01098-2. This article has 118 citations.
(nteli2024argininemiapathophysiologyand pages 3-5): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 4 citations.
(marzetaassas2024pathophysiologyofarginases pages 11-13): Patrycja Marzęta-Assas, Damian Jacenik, and Zbigniew Zasłona. Pathophysiology of arginases in cancer and efforts in their pharmacological inhibition. International Journal of Molecular Sciences, 25:9782, Sep 2024. URL: https://doi.org/10.3390/ijms25189782, doi:10.3390/ijms25189782. This article has 17 citations.
(borek2023arginase12inhibitor pages 1-1): Bartlomiej Borek, Julita Nowicka, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Joanna Brzezinska, Marcin Grzybowski, Paulina Stanczak, Paulina Pomper, Agnieszka Zagozdzon, Tomasz Rejczak, Krzysztof Matyszewski, Adam Golebiowski, Jacek Olczak, Kamil Lisiecki, Magdalena Tyszkiewicz, Magdalena Kania, Sylwia Piasecka, Anna Cabaj, Paulina Dera, Krzysztof Mulewski, Jacek Chrzanowski, Damian Kusmirek, Elzbieta Sobolewska, Marta Magdycz, Lukasz Mucha, Marek Masnyk, Jakub Golab, Marcin Nowotny, Elzbieta Nowak, Agnieszka Napiorkowska-Gromadzka, Stanislaw Pikul, Radoslaw Jazwiec, Karolina Dzwonek, Pawel Dobrzanski, Michael Meyring, Krzysztof Skowronek, Piotr Iwanowski, Zbigniew Zaslona, and Roman Blaszczyk. Arginase 1/2 inhibitor oatd-02: from discovery to first-in-man setup in cancer immunotherapy. Molecular cancer therapeutics, 22:807-817, Mar 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0721, doi:10.1158/1535-7163.mct-22-0721. This article has 37 citations and is from a peer-reviewed journal.
(grzybowski2025metabolomicreprogrammingof pages 1-2): Marcin Mikołaj Grzybowski, Yasemin Uçal, Angelika Muchowicz, Tomasz Rejczak, Agnieszka Kikulska, Katarzyna Maria Głuchowska, Małgorzata Szostakowska-Rodzoś, Agnieszka Zagożdżon, Tobias Bausbacher, Agnieszka Tkaczyk, Magdalena Kulma, Paulina Pomper, Michał Mlącki, Adam Konrad Jagielski, Roman Błaszczyk, Carsten Hopf, and Zbigniew Zasłona. Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor oatd-02 boosts anticancer immunity. Scientific Reports, May 2025. URL: https://doi.org/10.1038/s41598-025-03446-1, doi:10.1038/s41598-025-03446-1. This article has 24 citations and is from a peer-reviewed journal.

Artifacts

Citations

nteli2024argininemiapathophysiologyand pages 8-10
cane2025therolesof pages 1-2
clemente2020arginaseasa pages 3-6
nteli2024argininemiapathophysiologyand pages 2-3
li2022reviewofarginase pages 3-5
orellana2022newinsightsinto pages 1-2
orellana2022newinsightsinto pages 2-4
orellana2022newinsightsinto pages 7-9
palte2021cryoemstructuresof pages 1-2
zhu2026ureacycledysregulation pages 4-5
cane2025therolesof pages 2-3
cane2025therolesof pages 3-4
nteli2024argininemiapathophysiologyand pages 5-7
nteli2024argininemiapathophysiologyand pages 3-5
grzybowski2025metabolomicreprogrammingof pages 2-3
grzybowski2025metabolomicreprogrammingof pages 1-2
clemente2020arginaseasa pages 1-3
orellana2022newinsightsinto pages 6-7
marzetaassas2024pathophysiologyofarginases pages 13-14
orellana2022newinsightsinto pages 11-12
orellana2022newinsightsinto pages 12-14
xu2026molecularmechanismsand pages 3-4
karadima2025argininemetabolismin pages 1-2
pan2025harnessingaminoacid pages 8-10
cane2025therolesof pages 17-17
marzetaassas2024pathophysiologyofarginases pages 11-13
https://doi.org/10.3390/app14041647,
https://doi.org/10.1007/s13205-022-03326-9,
https://doi.org/10.1038/s41577-024-01098-2,
https://doi.org/10.1038/s42003-021-02444-z,
https://doi.org/10.1080/07388551.2021.1947962,
https://doi.org/10.1021/acs.jmedchem.4c01993,
https://doi.org/10.3390/ijms21155291,
https://doi.org/10.3892/ijmm.2026.5886,
https://doi.org/10.3390/ijms23126438,
https://doi.org/10.3390/ijms25189782,
https://doi.org/10.1038/s41598-025-03446-1,
https://doi.org/10.3389/fimmu.2026.1744890,
https://doi.org/10.3389/fonc.2026.1774392,
https://doi.org/10.1007/s00281-025-01038-9,
https://doi.org/10.1186/s10020-025-01099-4,
https://doi.org/10.1158/1535-7163.mct-22-0721,

📚 Additional Documentation

Notes

(ARG1-notes.md)

ARG1 (Arginase-1, human, UniProtKB:P05089) — review notes

Summary of function

ARG1 is the cytosolic, liver-type (type I) arginase, a binuclear manganese
metalloenzyme that catalyzes the terminal (fifth) step of the urea cycle:
L-arginine + H2O -> L-ornithine + urea (EC 3.5.3.1). It regenerates ornithine to
close the cycle and produces the urea that is excreted. It is a homotrimer, each
subunit binding two Mn(2+) ions. Beyond hepatic ureagenesis, ARG1 is
constitutively expressed in neutrophil granules and released during inflammation,
where local arginine depletion suppresses T-cell (and NK-cell) proliferation /
cytokine production — a myeloid immunoregulatory role. Loss-of-function variants
cause argininemia / arginase deficiency, a urea cycle disorder distinguished by
progressive spastic diplegia/paraparesis rather than the neonatal hyperammonemic
crises typical of proximal UCDs.

Key verbatim citations

Terminal urea-cycle step + disease:
PMID:3540966
Catalytic activity / Mn metalloenzyme:
PMID:17562323
PMID:21728378
PMID:21728378
Binuclear Mn cluster / structure:
PMID:16141327
Homotrimer / quaternary structure:
PMID:22959135
Neutrophil/granulocyte expression + azurophil granule + antimicrobial:
PMID:15546957
PMID:15546957
T-cell suppression via extracellular arginase / arginine depletion:
PMID:16709924
CMTM6 interaction (ARG1 identified as MS interactor in a PD-L1/CMTM6 study; ARG1 itself not the paper's focus):
UniProt: "INTERACTION WITH CMTM6, AND IDENTIFICATION BY MASS SPECTROMETRY" (RN[15], PMID:28813417).
Paper abstract is about CMTM6 regulating PD-L1; ARG1 is one MS-detected CMTM6 co-precipitant.
Sperm nucleus proteomics (HDA nucleus): PMID:21630459 is a bulk sperm-nuclear
proteome catalog (403 proteins); ARG1 detection is a large-scale MS hit, not a
dedicated study of nuclear ARG1 function.

Disease (dismech Arginase_Deficiency.yaml)

"progressive spastic diplegia or paraparesis, seizures, intellectual disability,
and growth retardation... relatively infrequent hyperammonemia compared to other
urea cycle disorders." Neurotoxicity from arginine + guanidino compounds.

GO term-definition checks (OLS)

GO:0004053 arginase activity = "L-arginine + H2O = L-ornithine + urea" (exact MF). CORE.
GO:0000050 urea cycle = full cycle; ARG1 does terminal step. CORE BP.
GO:0016813 hydrolase acting on C-N linear amidines = PARENT of arginase activity
(InterPro Mn-binding-site IEA); redundant/over-general vs GO:0004053 -> MODIFY.
GO:0046872 metal ion binding = PARENT of GO:0030145 manganese ion binding;
general -> MODIFY to GO:0030145 (which is verified, binuclear Mn cluster).
GO:0006527 L-arginine catabolic process = verified BP (breakdown of L-arginine). ACCEPT.
GO:0006525 arginine metabolic process = broader parent; keep (IBA/IEA).
GO:0030145 manganese ion binding = binds 2 Mn2+/subunit. CORE MF (contributes_to).
GO:0005829 cytosol = verified subcellular localization (arginase I cytosolic). CORE CC.
GO:0005737 cytoplasm = parent of cytosol; keep.
GO:0005576 extracellular region (IDA PMID:16709924) = neutrophil arginase released
extracellularly; real but non-core (secondary immune role).
GO:0035578 azurophil granule lumen / GO:0035580 specific granule lumen (Reactome
neutrophil degranulation) = real neutrophil granule localization; non-core.
GO:0005634 nucleus (HDA PMID:21630459) = bulk sperm-nucleus proteomics; likely
not a functional nuclear localization -> non-core / over-annotated.
GO:0070947 neutrophil-mediated killing of fungus (IMP PMID:15546957) = supported
by fungicidal-activity paper; non-core immune role.
GO:0042130 neg reg T cell proliferation (IDA/IBA PMID:16709924) = supported; non-core.
GO:0060336 neg reg type II IFN signaling (IMP PMID:16709924) = downstream immune
effect; keep as non-core.
GO:0042832 defense response to protozoan / GO:0046007 neg reg activated T cell
proliferation / GO:2000552 neg reg Th2 cytokine production (Ensembl GO_REF:0000107
IEA from mouse Q61176) = orthology-transferred mouse immune roles; keep non-core.
GO:0042127 regulation of cell population proliferation (ARBA IEA) = very general;
over-annotated relative to the specific T-cell terms -> MARK_AS_OVER_ANNOTATED.
GO:0005515 protein binding (IPI CMTM6, PMID:28813417) = uninformative; MS
interactor from a PD-L1 study -> non-informative binding, mark over-annotated.

Deep research

falcon deep-research launched (just deep-research-falcon human P05089 --alias ARG1);
FAILED after 600s ("All providers failed" — falcon endpoint timeout). No
-deep-research-falcon.md file produced. Review grounded in the UniProt record, all 9
cached publications, and dismech Arginase_Deficiency.yaml. No DR file fabricated.

📄 View Raw YAML

id: P05089
gene_symbol: ARG1
product_type: PROTEIN
status: INITIALIZED
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  Arginase-1 (liver-type/type I arginase) is the cytosolic, manganese-dependent
  ureohydrolase that catalyzes the terminal step of the urea cycle, hydrolyzing
  L-arginine and water to L-ornithine and urea (EC 3.5.3.1). It is a homotrimer,
  each subunit containing a binuclear manganese cluster required for catalysis.
  In the liver, where it is most abundantly expressed, arginase-1 regenerates
  ornithine to sustain the urea cycle and produces the urea that is excreted,
  making it central to nitrogen disposal; the distinct mitochondrial paralog
  arginase-2 (ARG2) operates in extrahepatic tissues. Arginase-1 is also
  constitutively expressed in the granules of human neutrophils and other
  myeloid cells, where it acts as an immunoregulatory enzyme: released into the
  extracellular space or phagolysosome, it depletes local L-arginine,
  suppressing T-cell and NK-cell proliferation and cytokine production and
  contributing to antimicrobial defense. Loss-of-function variants cause
  argininemia (arginase deficiency), a urea cycle disorder characterized by
  progressive spastic diplegia/paraparesis, seizures, and intellectual
  disability, with hyperammonemia occurring less frequently than in proximal
  urea cycle disorders.
alternative_products:
- name: '1'
  id: P05089-1
- name: 2 (Erythroid variant)
  id: P05089-2
  sequence_note: VSP_009330
- name: '3'
  id: P05089-3
  sequence_note: VSP_009331
existing_annotations:
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: enables
  review:
    summary: Phylogenetic (PAN-GO) inference of arginase activity, the defining and
      core molecular function of ARG1.
    action: ACCEPT
    reason: This is the correct, specific molecular function. Arginase activity (EC
      3.5.3.1, L-arginine + H2O = L-ornithine + urea) is directly demonstrated for
      human ARG1 by crystallographic and enzymatic studies, so the IBA inference is
      strongly supported.
    supported_by:
    - reference_id: PMID:17562323
      supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
        of l-arginine to yield l-ornithine and urea.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: is_active_in
  review:
    summary: Phylogenetic inference that ARG1 acts in the cytoplasm; consistent with
      its established cytosolic localization.
    action: KEEP_AS_NON_CORE
    reason: Correct but non-specific. ARG1 is a cytosolic enzyme; the more precise
      term GO:0005829 (cytosol), also annotated, better captures the localization.
      Retained as it is not wrong, but subordinate to the cytosol annotation.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0006525
    label: arginine metabolic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: Phylogenetic inference that ARG1 participates in arginine metabolism;
      correct but general.
    action: KEEP_AS_NON_CORE
    reason: Accurate at a general level. ARG1 catabolizes L-arginine, so involvement
      in arginine metabolism is correct; the more specific L-arginine catabolic process
      (GO:0006527) and urea cycle (GO:0000050) annotations capture the precise role.
    supported_by:
    - reference_id: PMID:17562323
      supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
        of l-arginine to yield l-ornithine and urea.
- term:
    id: GO:0042130
    label: negative regulation of T cell proliferation
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: Phylogenetic inference of an immunoregulatory role in suppressing T-cell
      proliferation, corroborated by direct experimental evidence in human granulocyte
      arginase.
    action: KEEP_AS_NON_CORE
    reason: Well-supported secondary (myeloid/immune) function. Extracellular arginase
      released from human granulocytes depletes arginine and suppresses T-cell proliferation.
      This is a genuine role but distinct from the core hepatic urea-cycle function.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: Human granulocyte arginase induces a profound suppression of
        T-cell proliferation and cytokine synthesis.
- term:
    id: GO:0000050
    label: urea cycle
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: Phylogenetic inference that ARG1 participates in the urea cycle; this
      is a core biological process for the enzyme.
    action: ACCEPT
    reason: ARG1 catalyzes the terminal step of the urea cycle, regenerating ornithine
      and releasing urea. This is a core biological process and the IBA inference
      is strongly supported by direct evidence.
    supported_by:
    - reference_id: PMID:3540966
      supporting_text: Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle
        in the liver of ureotelic animals.
- term:
    id: GO:0030145
    label: manganese ion binding
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: enables
  review:
    summary: Phylogenetic inference of manganese ion binding; ARG1 requires a binuclear
      Mn(2+) cluster for catalysis.
    action: ACCEPT
    reason: Directly supported by high-resolution crystal structures showing two manganese
      ions per subunit forming the catalytic binuclear cluster. Core molecular function
      cofactor requirement.
    supported_by:
    - reference_id: PMID:16141327
      supporting_text: The ultrahigh-resolution structure of the human arginase I-ABH
        complex yields an unprecedented view of the binuclear manganese cluster
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: is_active_in
  review:
    summary: Phylogenetic inference that ARG1 acts in the cytosol; this is the established
      subcellular location of type I arginase.
    action: ACCEPT
    reason: Arginase I is a cytosolic enzyme (in contrast to mitochondrial ARG2).
      This is the core localization where ureagenic arginine hydrolysis occurs.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  qualifier: enables
  review:
    summary: Automated (multiple-method) inference of arginase activity, mapped from
      RHEA:20569/EC:3.5.3.1 and orthology.
    action: ACCEPT
    reason: Correct and specific molecular function, consistent with the RHEA reaction
      L-arginine + H2O = L-ornithine + urea and the experimental annotations. Duplicate
      of the IBA/EXP arginase-activity annotations, which is acceptable.
    supported_by:
    - reference_id: PMID:16141327
      supporting_text: we demonstrate the inhibition of arginase activity by ABH in
        human and murine myeloid cells
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: Automated mapping from the UniProt Cytoplasm subcellular-location keyword.
    action: KEEP_AS_NON_CORE
    reason: Correct but general; cytosol (GO:0005829) is the more precise term for
      this cytosolic enzyme. Retained as a valid broader localization.
    supported_by:
    - reference_id: PMID:16141327
      supporting_text: exploration of inhibition in the immune response
- term:
    id: GO:0006525
    label: arginine metabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: involved_in
  review:
    summary: InterPro2GO mapping (arginase domain) to arginine metabolic process.
    action: KEEP_AS_NON_CORE
    reason: Correct but general. The specific catabolic role (L-arginine catabolic
      process, GO:0006527) and urea cycle (GO:0000050) better capture ARG1's function;
      this broad parent is acceptable as an IEA.
    supported_by:
    - reference_id: PMID:17562323
      supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
        of l-arginine to yield l-ornithine and urea.
- term:
    id: GO:0016813
    label: hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds,
      in linear amidines
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: enables
  review:
    summary: InterPro2GO mapping (ureohydrolase Mn-binding site) to a broad hydrolase-on-C-N-linear-amidines
      term.
    action: MODIFY
    reason: This is the parent term of the specific and experimentally established
      arginase activity (GO:0004053). Arginase hydrolyzes the C-N bond of the linear
      amidine L-arginine, so the term is not wrong, but it is over-general given the
      precise activity is known. Replace with the specific molecular function.
    proposed_replacement_terms:
    - id: GO:0004053
      label: arginase activity
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase is a binuclear manganese metalloenzyme that hydrolyzes
        L-arginine to form L-ornithine and urea
- term:
    id: GO:0042127
    label: regulation of cell population proliferation
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  qualifier: involved_in
  review:
    summary: ARBA machine-learning inference of a general role in regulating cell
      population proliferation.
    action: MARK_AS_OVER_ANNOTATED
    reason: Overly general electronic annotation. ARG1's proliferation-related effects
      are specifically on immune cells via arginine depletion (captured by the more
      specific negative regulation of T-cell proliferation terms). This broad, direction-less
      parent adds no functional specificity and is likely an over-annotation.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: Human granulocyte arginase induces a profound suppression of
        T-cell proliferation and cytokine synthesis.
- term:
    id: GO:0046872
    label: metal ion binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: enables
  review:
    summary: InterPro2GO mapping to a generic metal ion binding term.
    action: MODIFY
    reason: The specific metal bound is known to be manganese (a binuclear Mn(2+)
      cluster, two ions per subunit), captured by GO:0030145 (manganese ion binding),
      which is also annotated. The generic parent should be specialized.
    proposed_replacement_terms:
    - id: GO:0030145
      label: manganese ion binding
    supported_by:
    - reference_id: PMID:16141327
      supporting_text: The ultrahigh-resolution structure of the human arginase I-ABH
        complex yields an unprecedented view of the binuclear manganese cluster
- term:
    id: GO:0042832
    label: defense response to protozoan
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Ensembl-Compara orthology transfer from mouse Arg1 (Q61176) of a role
      in antiprotozoal defense.
    action: KEEP_AS_NON_CORE
    reason: This is an orthology-transferred (GO_REF:0000107, from mouse) immune role
      consistent with ARG1's known myeloid arginine-depletion function in antimicrobial
      defense, but it is a peripheral/species-informed role rather than the core hepatic
      function. Retained as non-core; the underlying human evidence is indirect.
    supported_by:
    - reference_id: PMID:15546957
      supporting_text: arginase I is localized in azurophil granules of neutrophils
        and constitutes a novel antimicrobial effector pathway, likely through arginine
        depletion in the phagolysosome
- term:
    id: GO:0046007
    label: negative regulation of activated T cell proliferation
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Ensembl-Compara orthology transfer from mouse Arg1 of negative regulation
      of activated T-cell proliferation.
    action: KEEP_AS_NON_CORE
    reason: Consistent with the well-documented human function whereby extracellular/granulocyte
      arginase depletes arginine and suppresses T-cell proliferation. A genuine secondary
      immunoregulatory role; retained as non-core.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: Human granulocyte arginase induces a profound suppression of
        T-cell proliferation and cytokine synthesis.
- term:
    id: GO:2000552
    label: negative regulation of T-helper 2 cell cytokine production
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Ensembl-Compara orthology transfer from mouse Arg1 of a role in limiting
      Th2 cytokine production.
    action: KEEP_AS_NON_CORE
    reason: Orthology-transferred (from mouse) immunoregulatory role. ARG1's arginine
      depletion suppresses T-cell cytokine synthesis; this specific Th2 term reflects
      the mouse ILC2/type-2 inflammation context. Retained as a plausible non-core
      immune role; the direct human evidence is limited.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: Human granulocyte arginase induces a profound suppression of
        T-cell proliferation and cytokine synthesis.
- term:
    id: GO:0000050
    label: urea cycle
  evidence_type: IEA
  original_reference_id: GO_REF:0000041
  qualifier: involved_in
  review:
    summary: UniPathway mapping (UPA00158) to the urea cycle.
    action: ACCEPT
    reason: Correct core biological process. ARG1 performs the terminal step of the
      urea cycle. Duplicate of the IBA urea-cycle annotation, which is acceptable.
    supported_by:
    - reference_id: PMID:3540966
      supporting_text: Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle
        in the liver of ureotelic animals.
- term:
    id: GO:0070947
    label: neutrophil-mediated killing of fungus
  evidence_type: IMP
  original_reference_id: PMID:15546957
  qualifier: involved_in
  review:
    summary: Experimental (IMP) annotation from the study showing arginase I in azurophil
      granules participates in fungicidal activity of human neutrophils.
    action: KEEP_AS_NON_CORE
    reason: Supported by the cited experimental study demonstrating a granulocyte
      antimicrobial effector role via arginine depletion. This is a genuine, well-evidenced
      secondary function in myeloid cells, distinct from the core hepatic urea-cycle
      role. Note UniProt now uses the closely related term GO:0070965 (positive regulation
      of neutrophil mediated killing of fungus) for the same evidence.
    supported_by:
    - reference_id: PMID:15546957
      supporting_text: arginase I is localized in azurophil granules of neutrophils
        and constitutes a novel antimicrobial effector pathway, likely through arginine
        depletion in the phagolysosome
- term:
    id: GO:0006527
    label: L-arginine catabolic process
  evidence_type: IMP
  original_reference_id: PMID:22959135
  qualifier: involved_in
  review:
    summary: Experimental (IMP) annotation from analysis of ARG1 mutations causing
      hyperargininemia, correlating loss of arginase activity with impaired L-arginine
      catabolism.
    action: ACCEPT
    reason: Core biological process. ARG1 catalyzes the breakdown of L-arginine; loss-of-function
      mutations cause hyperargininemia (accumulation of arginine), directly demonstrating
      its role in L-arginine catabolism. The curator assessed erythrocyte enzyme activity
      across a patient mutation series.
    supported_by:
    - reference_id: PMID:22959135
      supporting_text: It is caused by the deficient activity of the enzyme arginase
        I, encoded by the gene ARG1.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9956512
  qualifier: located_in
  review:
    summary: Reactome traceable-author annotation (ARG1 variant reaction) placing
      ARG1 in the cytosol.
    action: ACCEPT
    reason: Correct core localization for the cytosolic type I arginase. Consistent
      with the IBA cytosol annotation and biochemical evidence.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: EXP
  original_reference_id: PMID:16141327
  qualifier: enables
  review:
    summary: Direct experimental evidence of arginase activity from the 1.29-A crystal
      structure and inhibition study of human arginase I.
    action: ACCEPT
    reason: Core molecular function established by direct enzymatic assay and structural
      characterization of catalysis, including inhibition of arginase activity in
      human myeloid cells.
    supported_by:
    - reference_id: PMID:16141327
      supporting_text: we demonstrate the inhibition of arginase activity by ABH in
        human and murine myeloid cells
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: EXP
  original_reference_id: PMID:17562323
  qualifier: enables
  review:
    summary: Direct experimental evidence that (perdeuterated) human arginase I catalyzes
      hydrolysis of L-arginine to L-ornithine and urea with wild-type activity.
    action: ACCEPT
    reason: Core molecular function, directly assayed. The enzyme is explicitly characterized
      as a manganese metalloenzyme catalyzing L-arginine hydrolysis.
    supported_by:
    - reference_id: PMID:17562323
      supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
        of l-arginine to yield l-ornithine and urea.
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: EXP
  original_reference_id: PMID:21728378
  qualifier: enables
  review:
    summary: Direct experimental evidence (kinetic assay plus crystal structures)
      of human arginase I catalytic activity.
    action: ACCEPT
    reason: Core molecular function, directly measured. The enzyme is characterized
      as a binuclear manganese metalloenzyme hydrolyzing L-arginine to L-ornithine
      and urea.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase is a binuclear manganese metalloenzyme that hydrolyzes
        L-arginine to form L-ornithine and urea
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: EXP
  original_reference_id: PMID:16141327
  qualifier: located_in
  review:
    summary: Experimental subcellular localization of ARG1 to the cytoplasm.
    action: KEEP_AS_NON_CORE
    reason: Correct but general. The more precise cytosol term (GO:0005829) better
      captures the localization of this cytosolic enzyme. Retained as a valid broader
      annotation.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:28813417
  qualifier: enables
  review:
    summary: IPI annotation recording an ARG1-CMTM6 interaction detected by mass spectrometry
      in a study focused on CMTM6-mediated regulation of PD-L1.
    action: MARK_AS_OVER_ANNOTATED
    reason: Bare "protein binding" is uninformative and does not describe a molecular
      function. The supporting paper is a CRISPR/proteomics study of CMTM6 as a regulator
      of PD-L1; ARG1 appears only as one mass-spectrometry co-precipitant of CMTM6,
      with no evidence that this interaction is functionally relevant to ARG1. Per
      curation guidelines, avoid uninformative protein binding terms; this should
      not be treated as a core function.
    supported_by:
    - reference_id: PMID:28813417
      supporting_text: CMTM6 is a ubiquitously expressed protein that binds PD-L1 and
        maintains its cell surface expression.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: IDA
  original_reference_id: PMID:16709924
  qualifier: located_in
  review:
    summary: Direct experimental evidence that arginase I is liberated from human
      granulocytes and accumulates extracellularly during inflammation.
    action: KEEP_AS_NON_CORE
    reason: Genuine, experimentally demonstrated secondary localization. Neutrophil
      arginase is released into the extracellular space, where it depletes arginine.
      This is real but peripheral to the core intracellular (cytosolic) hepatic function.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: arginase I is liberated from human granulocytes, and very high
        activities accumulate extracellularly during purulent inflammatory reactions
- term:
    id: GO:0042130
    label: negative regulation of T cell proliferation
  evidence_type: IDA
  original_reference_id: PMID:16709924
  qualifier: involved_in
  review:
    summary: Direct experimental evidence that human granulocyte arginase suppresses
      T-cell proliferation via arginine depletion.
    action: KEEP_AS_NON_CORE
    reason: Well-supported secondary immunoregulatory function. Extracellular arginase
      depletes arginine, downregulating CD3-zeta and suppressing T-cell proliferation.
      Genuine but distinct from the core urea-cycle role.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: This T-cell phenotype is due to arginase-mediated depletion
        of arginine in the T-cell environment, which leads to CD3zeta chain down-regulation
        but does not alter T-cell viability
- term:
    id: GO:0060336
    label: negative regulation of type II interferon-mediated signaling pathway
  evidence_type: IMP
  original_reference_id: PMID:16709924
  qualifier: involved_in
  review:
    summary: IMP annotation of a downstream effect on IFN-gamma signaling, linked
      to arginase-mediated suppression of T-cell cytokine synthesis.
    action: KEEP_AS_NON_CORE
    reason: A downstream immunoregulatory consequence of arginine depletion (suppressed
      T-cell cytokine synthesis, including IFN-gamma responses) rather than a direct
      biochemical function of ARG1. Retained as non-core; the curator (UniProt) made
      this annotation from the full text.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: Human granulocyte arginase induces a profound suppression of
        T-cell proliferation and cytokine synthesis.
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798749
  qualifier: located_in
  review:
    summary: Reactome annotation (exocytosis of specific granule lumen proteins) placing
      ARG1 in the extracellular region upon neutrophil degranulation.
    action: KEEP_AS_NON_CORE
    reason: Consistent with the experimentally demonstrated release of neutrophil
      arginase into the extracellular space during degranulation. A genuine secondary
      localization, non-core relative to the cytosolic hepatic function.
    supported_by:
    - reference_id: PMID:16709924
      supporting_text: arginase I is liberated from human granulocytes, and very high
        activities accumulate extracellularly during purulent inflammatory reactions
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798751
  qualifier: located_in
  review:
    summary: Reactome annotation (exocytosis of azurophil granule lumen proteins)
      placing ARG1 in the extracellular region upon neutrophil degranulation.
    action: KEEP_AS_NON_CORE
    reason: Same as the other extracellular-region annotations - reflects release
      of granule-stored neutrophil arginase. Genuine secondary localization; non-core.
    supported_by:
    - reference_id: PMID:15546957
      supporting_text: arginase I is localized in azurophil granules of neutrophils
        and constitutes a novel antimicrobial effector pathway, likely through arginine
        depletion in the phagolysosome
- term:
    id: GO:0035578
    label: azurophil granule lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798751
  qualifier: located_in
  review:
    summary: Reactome annotation placing ARG1 in the azurophil granule lumen of neutrophils.
    action: KEEP_AS_NON_CORE
    reason: Directly supported by experimental localization of arginase I to azurophil
      granules of neutrophils. A genuine myeloid-cell localization, non-core relative
      to the core cytosolic hepatic function.
    supported_by:
    - reference_id: PMID:15546957
      supporting_text: arginase I is localized in azurophil granules of neutrophils
        and constitutes a novel antimicrobial effector pathway, likely through arginine
        depletion in the phagolysosome
- term:
    id: GO:0035580
    label: specific granule lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798749
  qualifier: located_in
  review:
    summary: Reactome annotation placing ARG1 in the specific granule lumen of neutrophils.
    action: KEEP_AS_NON_CORE
    reason: Reflects the granule storage of arginase I in neutrophils (the primary
      experimental report emphasizes azurophil granules; Reactome models both granule
      compartments). Genuine myeloid localization, non-core.
    supported_by:
    - reference_id: PMID:15546957
      supporting_text: in human leukocytes arginase I is constitutively expressed
        only in granulocytes
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: HDA
  original_reference_id: PMID:21630459
  qualifier: located_in
  review:
    summary: High-throughput proteomics detection of ARG1 in an isolated human sperm
      nucleus fraction.
    action: MARK_AS_OVER_ANNOTATED
    reason: This annotation derives from a large-scale catalog of 403 proteins detected
      in isolated sperm nuclei, not from a targeted study of nuclear ARG1 function.
      ARG1 is a well-established cytosolic enzyme with no known nuclear function; the
      detection likely reflects abundant cytoplasmic protein carryover in a bulk proteomic
      fraction. Marked as over-annotated rather than removed, as a mass-spec detection.
    supported_by:
    - reference_id: PMID:21630459
      supporting_text: 403 different proteins have been identified from the isolated
        sperm nuclei
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-70569
  qualifier: located_in
  review:
    summary: Reactome annotation (arginine + H2O => ornithine + urea reaction) placing
      ARG1 in the cytosol.
    action: ACCEPT
    reason: Core localization. This Reactome reaction is precisely the arginase reaction,
      correctly localized to the cytosol where the cytosolic type I arginase acts.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9959871
  qualifier: located_in
  review:
    summary: Reactome annotation (ARG1 gene expression) associated with cytosolic
      localization.
    action: ACCEPT
    reason: Correct core localization for the cytosolic type I arginase; duplicate
      of the other cytosol annotations, which is acceptable.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0004053
    label: arginase activity
  evidence_type: TAS
  original_reference_id: PMID:3540966
  qualifier: enables
  review:
    summary: Traceable-author statement of arginase activity from the original cloning
      of human liver arginase cDNA.
    action: ACCEPT
    reason: Core molecular function. The cloned cDNA conferred arginase activity on
      E. coli, and the enzyme is identified as EC 3.5.3.1 catalyzing the last urea-cycle
      step. Duplicate of the experimental arginase-activity annotations, which is
      acceptable.
    supported_by:
    - reference_id: PMID:3540966
      supporting_text: Arginase activity was detected in Escherichia coli cells transformed
        with the plasmid carrying lambda hARG6 cDNA insert.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: TAS
  original_reference_id: PMID:3540966
  qualifier: located_in
  review:
    summary: Traceable-author statement of cytoplasmic (liver) arginase localization.
    action: KEEP_AS_NON_CORE
    reason: Correct but general; cytosol (GO:0005829) is the more precise term. Retained
      as a valid broader localization.
    supported_by:
    - reference_id: PMID:21728378
      supporting_text: Arginase I is a cytosolic enzyme found predominantly in the
        liver, and arginase II is a mitochondrial enzyme found at highest concentrations
        in the kidney.
- term:
    id: GO:0006527
    label: L-arginine catabolic process
  evidence_type: TAS
  original_reference_id: PMID:3540966
  qualifier: involved_in
  review:
    summary: Traceable-author statement of ARG1's role in L-arginine catabolism (the
      terminal urea-cycle step) from the original cloning paper.
    action: ACCEPT
    reason: Core biological process. ARG1 hydrolyzes L-arginine as the last step of
      the urea cycle. Duplicate of the IMP L-arginine catabolic process annotation,
      which is acceptable.
    supported_by:
    - reference_id: PMID:3540966
      supporting_text: Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle
        in the liver of ureotelic animals.
core_functions:
- description: Catalyzes the terminal step of the urea cycle - the manganese-dependent
    hydrolysis of L-arginine to L-ornithine and urea - regenerating ornithine to close
    the cycle and releasing the urea that is excreted for nitrogen disposal.
  molecular_function:
    id: GO:0004053
    label: arginase activity
  supported_by:
  - reference_id: PMID:17562323
    supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
      of l-arginine to yield l-ornithine and urea.
  directly_involved_in:
  - id: GO:0000050
    label: urea cycle
  locations:
  - id: GO:0005829
    label: cytosol
- description: Requires a binuclear manganese cluster (two Mn(2+) ions per subunit)
    for catalytic activity; manganese binding is an essential cofactor requirement
    of the arginase active site.
  molecular_function:
    id: GO:0004053
    label: arginase activity
  contributes_to_molecular_function:
    id: GO:0030145
    label: manganese ion binding
  supported_by:
  - reference_id: PMID:16141327
    supporting_text: The ultrahigh-resolution structure of the human arginase I-ABH
      complex yields an unprecedented view of the binuclear manganese cluster
  locations:
  - id: GO:0005829
    label: cytosol
- description: Breaks down L-arginine (L-arginine catabolic process); loss of this
    activity in ARG1 causes hyperargininemia/argininemia, a urea cycle disorder.
  molecular_function:
    id: GO:0004053
    label: arginase activity
  directly_involved_in:
  - id: GO:0006527
    label: L-arginine catabolic process
  supported_by:
  - reference_id: PMID:22959135
    supporting_text: It is caused by the deficient activity of the enzyme arginase
      I, encoded by the gene ARG1.
  locations:
  - id: GO:0005829
    label: cytosol
proposed_new_terms: []
suggested_questions:
- question: Beyond arginine depletion in the extracellular space/phagolysosome, does
    human ARG1 have any direct, arginine-independent immunoregulatory function, or
    are all of its immune effects a consequence of local arginine catabolism?
- question: Is the reported nuclear detection of ARG1 in sperm (PMID:21630459) functionally
    meaningful, or does it reflect cytoplasmic carryover in bulk proteomics?
suggested_experiments:
- hypothesis: Argininemia severity is determined by residual arginase activity, which
    depends on how a given missense variant perturbs the Mn-binding active site or
    the R308 trimerization interface.
  description: Structure-guided kinetic characterization of clinically observed missense
    variants (e.g. those affecting the Mn-binding residues or the R308 trimerization
    interface) to correlate residual arginase activity with argininemia phenotype
    severity.
- hypothesis: The immunosuppressive effect of neutrophil ARG1 is entirely due to enzymatic
    depletion of extracellular L-arginine.
  description: Quantitative measurement of local arginine depletion and downstream
    T-cell CD3-zeta levels using ARG1-deficient versus wild-type human neutrophils
    to dissect the enzymatic basis of the immunosuppressive effect.
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO
    terms
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000041
  title: Gene Ontology annotation based on UniPathway vocabulary mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning models
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
  findings: []
- id: PMID:15546957
  title: Arginase I is constitutively expressed in human granulocytes and participates
    in fungicidal activity.
  findings:
  - statement: Arginase I is constitutively expressed only in granulocytes among human
      leukocytes and is localized in azurophil granules, constituting an antimicrobial
      effector pathway via arginine depletion in the phagolysosome.
    supporting_text: arginase I is localized in azurophil granules of neutrophils
      and constitutes a novel antimicrobial effector pathway, likely through arginine
      depletion in the phagolysosome
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; abstract-only cache but the myeloid-arginase/azurophil-granule
      findings are the source for the neutrophil localization and antimicrobial annotations.
- id: PMID:16141327
  title: Crystal structure of human arginase I at 1.29-A resolution and exploration
    of inhibition in the immune response.
  findings:
  - statement: The 1.29-A structure reveals the binuclear manganese cluster of human
      arginase I and the structural basis of catalysis and inhibition.
    supporting_text: The ultrahigh-resolution structure of the human arginase I-ABH
      complex yields an unprecedented view of the binuclear manganese cluster
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; source for the binuclear Mn cluster and experimental
      arginase-activity annotations.
- id: PMID:16709924
  title: Suppression of T-cell functions by human granulocyte arginase.
  findings:
  - statement: Arginase I released from human granulocytes accumulates extracellularly
      during inflammation and suppresses T-cell proliferation and cytokine synthesis
      by depleting arginine, downregulating the CD3-zeta chain.
    supporting_text: This T-cell phenotype is due to arginase-mediated depletion of
      arginine in the T-cell environment, which leads to CD3zeta chain down-regulation
      but does not alter T-cell viability
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; source for extracellular localization and the T-cell
      suppression / IFN-signaling immune annotations.
- id: PMID:17562323
  title: Expression, purification, assay, and crystal structure of perdeuterated human
    arginase I.
  findings:
  - statement: Human arginase I is a manganese metalloenzyme that catalyzes hydrolysis
      of L-arginine to L-ornithine and urea, confirmed by assay and X-ray structure.
    supporting_text: Arginase is a manganese metalloenzyme that catalyzes the hydrolysis
      of l-arginine to yield l-ornithine and urea.
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; direct experimental support for arginase activity
      and Mn dependence.
- id: PMID:21630459
  title: Proteomic characterization of the human sperm nucleus.
  findings:
  - statement: A large-scale proteomic catalog identified 403 proteins in isolated
      human sperm nuclei; ARG1 is one large-scale MS detection, not a targeted study
      of nuclear arginase function.
    supporting_text: 403 different proteins have been identified from the isolated
      sperm nuclei
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: PubMed-verified; bulk sperm-nucleus proteome. Underpins the HDA
      nucleus annotation, which is likely cytoplasmic carryover rather than functional
      nuclear localization.
- id: PMID:21728378
  title: Binding of alpha,alpha-disubstituted amino acids to arginase suggests new
    avenues for inhibitor design.
  findings:
  - statement: Arginase is a binuclear manganese metalloenzyme that hydrolyzes L-arginine
      to L-ornithine and urea; arginase I is cytosolic and predominantly hepatic,
      whereas arginase II is mitochondrial.
    supporting_text: Arginase I is a cytosolic enzyme found predominantly in the liver,
      and arginase II is a mitochondrial enzyme found at highest concentrations in
      the kidney.
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; full text explicitly contrasts cytosolic ARG1 with
      mitochondrial ARG2 and confirms catalytic activity.
- id: PMID:22959135
  title: Analysis of novel ARG1 mutations causing hyperargininemia and correlation
    with arginase I activity in erythrocytes.
  findings:
  - statement: Hyperargininemia is caused by deficient arginase I activity encoded
      by ARG1; the R308 residue is important for assembly of the ARG1 homotrimer.
    supporting_text: Our study reinforced the role of Arg308 residue for assembly
      of the ARG1 homotrimer.
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; source for the L-arginine catabolic process IMP
      annotation and homotrimer quaternary structure.
- id: PMID:28813417
  title: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
  findings:
  - statement: This study identifies CMTM6 as a regulator of PD-L1 cell-surface expression;
      ARG1 appears only as a mass-spectrometry co-precipitant of CMTM6, providing
      no functional evidence for an ARG1-specific role.
    supporting_text: CMTM6 is a ubiquitously expressed protein that binds PD-L1 and
      maintains its cell surface expression.
  reference_review:
    relevance: LOW
    correctness: MISCITED
    review_notes: PubMed-verified paper, but it does not support a functional ARG1
      annotation - ARG1 is only an MS interactor of CMTM6, and the resulting bare
      protein-binding term is uninformative.
- id: PMID:3540966
  title: Molecular cloning and nucleotide sequence of cDNA for human liver arginase.
  findings:
  - statement: Human liver arginase (EC 3.5.3.1) catalyzes the last step of the urea
      cycle; cloned cDNA conferred arginase activity, and inherited deficiency causes
      argininemia.
    supporting_text: Arginase (EC 3.5.3.1) catalyzes the last step of the urea cycle
      in the liver of ureotelic animals.
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: PubMed-verified; original cloning paper, foundational for arginase
      activity, cytoplasmic localization, and urea-cycle/L-arginine-catabolism annotations.
- id: Reactome:R-HSA-6798749
  title: Exocytosis of specific granule lumen proteins
  findings: []
- id: Reactome:R-HSA-6798751
  title: Exocytosis of azurophil granule lumen proteins
  findings: []
- id: Reactome:R-HSA-70569
  title: arginine + H2O => ornithine + urea [ARG1]
  findings: []
- id: Reactome:R-HSA-9956512
  title: ARG1 variants don't synthesize urea and ornithine
  findings: []
- id: Reactome:R-HSA-9959871
  title: ARG1 gene expression
  findings: []

ARG1

Gene Description

Existing Annotations Review

Core Functions

Catalyzes the terminal step of the urea cycle - the manganese-dependent hydrolysis of L-arginine to L-ornithine and urea - regenerating ornithine to close the cycle and releasing the urea that is excreted for nitrogen disposal.

Requires a binuclear manganese cluster (two Mn(2+) ions per subunit) for catalytic activity; manganese binding is an essential cofactor requirement of the arginase active site.

Breaks down L-arginine (L-arginine catabolic process); loss of this activity in ARG1 causes hyperargininemia/argininemia, a urea cycle disorder.

References

Suggested Questions for Experts

Suggested Experiments

Deep Research

Falcon

Comprehensive Research Report on Human ARG1 (Arginase-1, P05089)

1. Gene and Protein Identity

2. Enzymatic Function and Catalytic Mechanism

2.1 Primary Reaction

2.2 Catalytic Mechanism

2.3 Substrate Specificity

3. Quaternary Structure and Assembly

4. Subcellular Localization and Tissue Distribution

5. Biochemical Pathways

5.1 The Urea Cycle

5.2 Downstream Metabolic Pathways

5.3 Competition with Nitric Oxide Synthase

6. Role in Immune Regulation

6.1 Macrophage Polarization

6.2 T Cell Suppression

7. Disease Associations

7.1 Argininemia (Arginase Deficiency)

7.2 Cancer and Immunotherapy

8. Summary

Artifacts

Citations

📚 Additional Documentation

Notes

ARG1 (Arginase-1, human, UniProtKB:P05089) — review notes

Summary of function

Key verbatim citations

Disease (dismech Arginase_Deficiency.yaml)

GO term-definition checks (OLS)

Deep research

📄 View Raw YAML